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Introduction
1. Introduction
The oral route of drug administration is the most important method of administering drug
for systemic effect. More than 90% of the drugs used to produce systemic effect are administered
by the oral route1  Different types conventional dosage forms that are administered orally, such as
solution, suspension, emulsion, tablets and capsules etc release the API into the absorption pool
immediately.  Upon administration of the dosage form the therapeutic plasma concentration is
reached very quickly but does not maintain the drug level in the blood for an extended period of
time.  They have a very short duration of action. The short duration of action is due to inability
of conventional dosage form to control temporal delivery. A drug blood level vs. time profile for
a conventional dosage form administered orally is shown in the figure below. 
Figure  no.  1  Plasma  drug  concentration  profiles  for  conventional  tablet  or  capsule
formulation,  a  sustained  release  formulation  and  a  zero  order  controlled  release
formulation. 
To  achieve  and  maintain  the  concentration  of  an  administered  drug  within  therapeutically
effective range,  it  is often necessary to take drug dosage several  times and thus results  in a
fluctuating drug level in plasma which is shown in the figure below.
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Figure  no.  1  Plot of Cp versus time for multiple oral doses showing Cpmax and Cpmin
An ideal controlled drug delivery2 system delivers the drug at a predetermined rate, locally or
systemically for a specified period of time. Controlled drug delivery system not always release
the drug by zero order kinetics .It may release by first order or any other kinetic model. 
Figure no. 3 A hypothetical plasma concentration - time profile from conventional multiple
dosing and single dose of sustained and controlled delivery formulations
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In this case the level of the drug in the blood and the time required to reach that level depend
upon the dose and the dosing interval.  The potential  problems associated with multiple dose
therapy are :
1. If the interval is not appropriate, larger peaks and valley may results which may leads to
adverse or toxic effects.
2. The drug blood level may not be within the therapeutic range at sufficiently early times,
which is important for certain diseases.
3. Poor patient compliance is observed as multiple daily doses are required.
So,  these  are  the  factors  which  lead  to  the  investigation  of  sustained  release  drug  delivery
system.
2.1.1 Layered tablets 
Layered  tablets are composed of two or three layers of granulation compressed together.
These  are  usually  consisting  of  two  and  sometimes  three  layers.  They  have  appearance  of
sandwich because the edges of each layer are exposed. 
Fixed dose combinations with two or more ingredients can be formulated together in spite of
actives having different physicochemical characteristics.
 Active-Active  incompatibility.
 Actives may be thermal sensitive. 
 Actives may be moisture sensitive. 
2.1.2 Classification of layered tablets 
A  Layered tablets are classified as 3 types according to number of active ingredients 
 Trilayered tablets having three different active ingredients.
 Bilayered tablets having two different active ingredients.
 Bilayered tablets having single active ingredients.
        B   Layered tablets are classified as the formulation type they are
 Bilayer tablets contain one immediate release and other sustained release.
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 2 Bilayer tablets contain both immediate release.
 Bilayer tablets of   contain sustained and other inert layer as supporting.
 Bilayer tablets of one sustained release and other inert layer as protective.
2.1.3   Disadvantages of multilayer tablets
 Labour cost is high.
 Producion reduces to less than half.
 Proper weight adjustment of each layer is difficult during running of batch.
 Chances of lack of proper bonding of layers.
 Layer separation during storage.
2.1.4 Bi-Layer tablet
Bilayer tablet is defined as tablet consisting of two discrete zones consisting of same or
different API intended for therapeutic action. A bilayer  tablets consist of two layers. Bilayer
tablets allows for designing and modulating the dissolution and release characteristics.
      Immediate release layer- Contains loading dose or I stdrug
      Sustained release layer- Contains maintenance dose or IInd drug
Immediate release layer of the dosage form contains the loading dose that delivers the entirety of
its drug content at once after administration for the purpose of providing a rapid rise of drug
concentration in the blood stream. 
Sustained release layer of the dosage form contains the maintenance dose that gradually releases
its drug content over a given period of time after administration for the purpose of providing a
constant concentration of drug in lo the blood stream.
With two or more ingredients can be formulated together in spite of actives having different
physico–chemical characteristics.
• Active -Active incompatibility
• Actives may be thermal or moisture sensitive.
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• Bilayer  tablets  allows  for  designing  and  modulating  the  dissolution  and  release
characteristics.
2.1.5 Bi-Layer Tablets are ideal for:
• Single agent pharmaceutical products. 
• Combination therapy agent tablets with both agents in the same layer. 
• Creation of new interrmediate dose.
• Titration and fine dose adjustments. 
2.1.6 Advantages of bilayer tablets 
Bilayer  tablet have all  advantages  of combination drug delivery as well  as additional
advantages. 
 Two or more drugs having different having different pharmacological  action can be
given in single dose
 Two or more drugs having different mechanism of action have been given in single
dose
 Increase in patient compliance 
 Decrease resistance of drug especially in case of antibiotics 
 Cost effective
 Synergistic effect of two drugs 
 Two incompatible drugs can be given. 
 One drug is immediate release other is sustained release can be given.
 One  is  moisture  sensitive  other  is  not  moisture  sensitive  can  be  given  in  bilayer
tablets.
 One is enteric coated granules other drug is not enteric coated.
 Attractive appearance for marketing purpose. 
 Different color layers for easy identification for a patient.
 One layer is water impermeable other layer for drug release such as mucoadhesion.    
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 Drug release of one which affects the release of other drug can be given as bilayer
tablets.
2.1.7 Potential rationale for formulation development
 Patient compliance
 Immediate release of loratadine produces antihistamine effect without sedation.
 Minimum physical and chemical interaction
 Sustained effect of pseudoephedrine produce nasal decongestants effect for prolong
period. 
 Multiple medication management
 Economical than producing separate products for each active agent.
2.2 Sustained release drug delivery system3,4,
 The  term  ‘sustained  release’  is  known  to  have  existed  in  the  medical  and  pharmaceutical
literature  for  many decades.  The term sustained release  indicates  an initially release  of  drug
sufficient  to  provide  a  therapeutic  dose  soon  after  administration  and  gradual  release  over
extended period. 
The objective of sustained release of drug, in general way is to modify the normal behavior of
drug molecule in a physiological environment. It can lead to the following.
1) Sustaining  drug  action  at  a  predetermined  rate  by  maintaining  a  relatively  constant,
effective drug level in the body with minimization of undesirable side effects.
2) Localization of drug action by spatial placement of controlled release system usually rate
controlled adjacent to the or in the diseased tissue or organ.
3) Targeting  drug  action  by  using  carriers  or  chemical  derivatives  to  deliver  drug  to
particular target cell type.
    
2.2.1 Advantages of sustained Release Dosage Forms5:
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All sustained release products share the common goal of improving drug therapy over
that  achieved  with  their  non-sustained  counterparts.  This  improvement  in  drug  therapy  is
represented by several potential advantages which are given below:
1. Better utilization of drug.
2. Reduced dose frequency 
3. Improvement of patient compliance
4. Usage of less total drug
5. Reduction in local or systemic side effects 
6. Minimization of drug accumulation (with chronic dosage)
7. More consistent and prolonged therapeutic effect.
8. Improvement in treatment efficiency
9. Improvement in speed of control of medical conditions 
10. Reduction in drug blood level fluctuation
11. Improvement in bioavailability for some drugs 
Generally,  oral  controlled  release  dosage  forms  should  not  be  developed  unless  the
recommended  dosage  interval  for  the  controlled  release  dosage  form is  longer  than that  for
immediate release dosage form or unless significant clinical advantages for the controlled release
dosage form can be justified like the decreased side effects compared to the immediate release or
conventional dosage form.
2.3 Matrix Devices:
 A  matrix  device  as  the  name  implies,  consists  of  a  drug  dispersed  homogeneously
throughout  a  rate-controlling  medium.  These  include  dissolution  controlled  release  systems,
diffusion controlled release systems and the combination of dissolution and diffusion controlled
release  systems.  Release  characteristics  from  matrix  systems  depend  on  the  nature  of  the
polymers, the additives, the drug and the geometry of the systems.
2.3.1 Reasons for restoring to matrix embedding:
  Matrix systems offer several advantages such as controlling the dissolution rate of drugs having
high  aqueous  solubility.  They are easy to make and can be made to  release  high molecular
weight compounds . As the drug is dispersed in the matrix system, accidental leakage of the total
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drug component is less likely to occur and controlling the release kinetics of these devices is
easier than for other systems, i.e. coated systems. Other advantages 11 include:
 Excipients used in these systems are generally cheap and are usually regarded as safe.
 Capable of sustaining high drug loading.
 Easy to manufacture by using commonly available equipment, by direct compression,
wet granulation or by roll compaction.
 Possible to obtain different types of release profile: Zero order, first order, bimodal
etc.
2.3.2 Matrix embedding techniques
      These systems can be considered as two groups:
i) That with drug particles dispersed in soluble matrix, with drug being available as
the matrix dissolves or swells and dissolves.(Hydrophilic colloid matrices)
ii) Those  with  drug  particles  dispersed  in  an  insoluble  matrix,  with  drug  being
available as a solvent enters the matrix and dissolves the particles (lipid matrices
and insoluble polymer matrices).
Release of drugs dispersed in a soluble matrix relies on slow dissolution of the matrix to provide
controlled release.  In the case of drugs incorporated into an insoluble matrix, release follows
penetration of fluid, followed by dissolution of the drug particles and diffusion through fluid
filled  pores.  The  drug  release  from  lipid  matrix  systems  depends  on  an  aqueous  medium
dissolving the channeling agents, which leaches out of the compact so forming porous matrix of
tortuous capillaries. 
The  active  agent  dissolves  in  the  aqueous  medium and  through  the  water  filled  capillaries
diffuses out of the matrices.
(a) Hydrophilic colloid matrix system
       This delivery system is also called swellable-soluble matrices.  In  general  they comprise a
compressed mixture of drug and water swellable hydrophilic polymer. On contact with water the
hydrophilic  colloid  component  swell  to  form a  hydrated  matrix  layer.  This  then  control  the
further diffusion of water into the matrix. Diffusion of the drug through the hydrated matrix layer
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controls its rate of release. The outer hydrated matrix layer will erode as it becomes more dilute;
the rate of erosion depends on the nature of the colloid. 
Hydrophilic colloid gel can be regarded as a network of polymer fibrils that interlink in
some way.  There is also a continuous phase in the interstices between the fibrils through which
the drug diffuses. These interstices connect together and are analogous to the tortuous capillaries
seen in wax matrix. The tortuosity of the diffusion path and the ‘microviscosity’ and interactions
within the interstitial continuum govern the diffusion of the drug through the hydrated gel layer,
and hence the release of the drug. 
Components of a hydrophilic matrix delivery system 
 Active drug
 Hydrophilic colloid(s)
 Solubilizer / pH modifier
 Compression aid 
 Lubricant
 Glidant
Matrix forming agents for hydrophilic matrices
 Hydrophilic colloids which, on contact with water,  form a hydrated gel  that remains
‘sufficiently  intact’  during  passage  through  the  GIT,are  suitable  matrix  forming  agent  for
hydrophilic matrices. 
Examples of hydrophilic colloids include:
 Hydroxy propyl methyl cellulose (High viscosity grades 
 Hydroxy ethyl cellulose and Hydroxy propyl cellulose
 Sodium carboxymethyl cellulose
 Alginates 
 Xanthan gum 
 Polyethylene oxide
 Carbopol
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(b) Lipid matrix system 
 The lipid matrix systems are prepared from blends of powdered components. The active
compound is  contained  in  a  hydrophobic  matrix  that  remains  intact  during the drug release.
Release depends on an aqueous medium dissolving the channeling agent, which leaches out of
the compact so forming a porous matrix of tortuous capillaries. The active agent dissolves in the
aqueous medium and, by way of the water-filled capillaries, diffuses out of the matrix. 
A typical lipid matrix system consists of:
 Active drug 
 Wax matrix former 
 Channeling agent
 Solubilizer and ph modifier
 Antiadherant/Glidant
 Lubricant
(c)  Insoluble polymer matrix system
 An insoluble inert matrix system is one in which a drug is embedded in an inert polymer
which is  not  soluble in  the gastrointestinal  fluid.  Drug release  from inert  matrices  has  been
compared to the leaching from a sponge. 
      The release rate depends on drug molecules in aqueous solution diffusing through a
network of capillaries formed between compacted polymer particles. The release rate of drug
from an inert matrix can be modified by changes in the porosity and tortuosity of the matrix, i.e.
its pore structure.  The addition of pore forming hydrophilic salts or solute will have a major
influence,  as  can  the  manipulation  of  processing  variables.  Compression  force  controls  the
porosity of the matrix, which in turn control drug release. Generally a more rigid and less porous
matrix will release drug more slowly than a less consolidated matrix.
Methods:
The following methods  may be used to disperse the drug in the matrix material.
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i) Solvent evaporation techniques, in which a solution of matrix material is prepared
in a suitable solvent, the drug is either dissolved or dispersed in it and then the
solvent is removed by evaporation.
ii) Fusion technique, in which the drug is blended into the molten matrix material at
temperatures slightly above the melting point of the drug and then the blend is
either spray congealed or solidified and flaked or poured on a cold rotating drum
to form sheets,  which are then milled and screened to form granules.  By this
technique a more uniform dispersion can be prepared.
iii) Direct compression technique, in which dry blends of drug and matrix material
are prepared, slugged and granulated.
2.3.3 Factors affecting release of drug from matrix
The following factors affect the release of drug from matrix systems. 
• Viscosity of polymer 
• Mixture of polymer 
• Ratio of polymer to drug
• Particle size of drug 
• Tablet thickness 
• Compression pressure 
• Added diluents 
• Microenvironment pH of matrix 
• Tablet surface area 
• Entrapped air in tablet
• Drug solubility 
2.3.4 Disadvantages of Controlled Release Dosage Forms6:
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1) Increased variability among dosage units. 
2) Toxicity due to dose dumping.
3) Poor in vitro-in vivo correlation.
4) Reduced potential for dosage adjustment.
5) Possible reduction in systematic availability
6) Delayed onset of action, which is not suitable for disease where quick onset
and sustained action is required. E.g. Pain and inflammation requires   quick
onset and sustained action by the NSA
1. Water  insoluble,  inert
materials 
Polyethylene, 
Polyvinylchloride,
Methylacrylate-methacrylate  copolymer,
Ethylcellulose.
2. Hydrophobic  materials,
insoluble-erodable
(waxes)
Sterylalcohol,  Stericacid,  Polyethylene  glycol,
Carnaubawax,  Casterwax,  Polyethylene  glycol
monosterate, Triglycerides. 
3. Hydrophilic  materials 
a) synthetic gums 
Hydroxypropylmethylcellulose,Sodium  carboxy
methylcellulose  (400  cps,  4000  cps),  Hydroxy
ethyl cellulose. 
b) Natural gums Guar gum, Chitosan, Gum acacia, Tamarind seed
polyose,  Locustbeangum,  Sod.  Alginate,  Karaya
gum, Pectins, Xanthan gum.
Table No.1 Classification of retardant materials used in matrix tablets
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2. Literature review
2.1 Littérature survey on bilayer tablet
Patra  C.N.  et  al7    developed  a  bilayer  tablet  of  propranolol  hydrochloride  using
superdisintegrant  sodium  starch  glycolate  for  the  fast  release  layer  and  water  immiscible
polymers such as ethylcellulose, Eudragit RLPO and Eudragit RSPO for the sustaining layer. In
vitro  dissolution studies were carried out in a USP 24 apparatus I.  The formulations gave an
initial burst effect to provide the loading dose of the drug followed by sustained release for 12 h
from the sustaining layer of matrix embedded tablets.  In vitro dissolution kinetics followed the
Higuchi model via a non-Fickian diffusion controlled release mechanism after the initial burst
release. FTIR studies revealed that there was no interaction between the drug and polymers used
in the study. Statistical analysis (ANOVA) showed no significant difference in the cumulative
amount of drug release after 15 min, but significant difference (p < 0.05) in the amount of drug
released after 12 hrs from optimized formulations was observed.
Chinam niranjan patra et al  developed a Bilayered tablet of propanolol hydrochloride for the
fast release layer and water immiscible polymers such as ethyl  cellulose, Eudragit RLPO and
Eudragit RSPO for the sustaining release layer  the formulation gave an initial burst effect  to
provide  the  loading  dose  of  the  drug  followed  by  sustained  release  for  12  hours  from the
sustaining layer of matrix embedded tablets.  The Both layers were prepared by wet granulation
process.
Shiyani et al 8  prepared bi-layer tablet of Metoclopramide Hydrochloride (MTH) and Ibuprofen
(IB) for the effective treatment of migraine. MTH and IB were formulated as immediate and
sustained release layer respectively. MTH was formulated as immediate release layer MTH was
formulated  as  immediate  release  layer  by  using  various  disintegrants  like  Ac-Di-
Sol,Polyplasdone XL,Explotab, Agar and Gellan Gumand IB was formulated as sustained release
layer using hydrophilic poymer  HPMC K4M.
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Vishnu M et  al9  The purpose of this research was to study mucoadhesive bilayer buccal tablets
of propranolol hydrochloride using the bioadhesive polymers sodium alginate (Na-alginate) and
Carbopol 934P (CP) along with ethyl cellulose as an impermeable backing layer.  The tablets
were  evaluated  for  weight  variation,  thickness,  hardness,  friability,  surface  ph,mucoadhesive
strength, swelling index, in vitro drug release, ex vivo drug permeation, ex vivo mucoadhesion,
and in vivo pharmacodynamics in rabbits. Tablets containing Na-alginate and CP in the ratio of
5:1 (F2) had the maximum percentage of in vitro drug release without disintegration in 12 hours. 
The swelling index was proportional to Na-alginate content and inversely proportional to
CP content. The surface ph of all tablets was found to be satisfactory (7.0 ± 1.5), close to neutral
pH; hence, buccal cavity irritation should not occur with these tablets. The mechanism of drug
release was found to be non-Fickian diffusion and followed zero-order kinetics. The formulation
F4 was optimized based on good bioadhesive strength (28.9 ± 0.99 g) and sustained in vitro drug
permeation (68.65% ± 3.69% for 12 hours). 
Rajashree Masareddy et al 10 developed floating matrix tablet of Riboflavin single and bilayer
tablets were prepared by direct  compression technique using polymers hydroxypropyl  methyl
cellulose,  carbopol  971  P  and  other  standard  excipients.   Carbopol  containing  tablets  were
retained in stomach by mucoadhesive mechanism and HPMC containing tablets were retained in
stomach by non-mucoadhesive (floating) mechanism.
 Remaya P.N.  et  al11 developed  the Bilayer  tablets  of  Ibuprofen  and  Methocarbamol  using
Povidone K-30 as binder wet granulation process was used for the formulation of two layers and
the tablet was film coated.   This formulation is  developed to separate  the incompatible drug
substances  methocarbomol  layer  blend  is  initially  pre-compressed  with  low  hardness  and
Ibuprofen layer blend compressed over it.
Krishnaiah Y.S.R. et al  (2002)12 formulated three-layer matrix tablets of Metoprolol Tartrate by
compressing on both sides of guar gum matrix tablet granules of Metoprolol Tartrate with either
50 or 75 mg of guar gum granules as release retardant layers.  The amount of Metoprolol Tartrate
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released from the three layer matrix tablets at different time intervals was estimated by using a
HPLC method.
Narendra C.  et al13 developed an optimized gastric floating drug delivery system (GFDDS)
containing metoprolol tartrate (MT) as a model drug by the optimization technique. A 23 factorial
design was employed in formulating the GFDDS with total polymer content-to-drug ratio (X1),
polymer-to-polymer ratio (X2), and different viscosity grades of hydroxypropyl methyl cellulose
(HPMC) (X3) as independent variables. Four dependent variables were considered: percentage of
MT  release  at  8  hours,  T50%,  diffusion  coefficient,  and  floating  time.  The  main  effect  and
interaction terms were quantitatively evaluated using a mathematical model. The results indicate
that X1 and X2 significantly affected the floating time and release properties, but the effect of
different viscosity grades of HPMC (K4M and K10M) was nonsignificant. Regression analysis
and numerical  optimization were performed to  identify the best  formulation.  Fickian  release
transport  was  confirmed  as  the  release  mechanism  from  the  optimized  formulation.  The
predicted  values  agreed  well  with  the  experimental  values,  and  the  results  demonstrate  the
feasibility of the model in the development of GFDDS.
R. Nagaraju et al14 developed Bilayer sustained release tablets of salbutamol and Theophylline
both  layers  were  prepared  by  wet  granulation  technique.   First  layer  (white  layer)  was  the
immediate release layer where the salbutamol was present.  The Second layer (blue layer) was
the  sustained release  layer  where  the  salbutamol  and  Theophylline  both  were  present.   The
release  of  theophylline  should  be  completed  within  8  hours,  so  that  the  Theophylline
concentration in the body can be maintained for 12 hours.  The release of the salbutamol should
be completed with in 8 hours.
M A Naeem  et al15 developed controlled release Bilayer tablets containing microencapsulated
tramadol  and  Acetaminophen  coacervation  via  temperature  change  was  the  encapsulation
method used for the preparation of the microparticles with ethyl cellulose of medium viscosity as
the  polymer  for  extending  drug  release.   The  microparticles  of  two  drugs  were  prepared
separately  and  then  compressed  into  bilayer  tablets.   Prolonged  release  upto  12  hours  was
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achieved  thus  making  it  feasible  to  attain  educed  frequency  of  administration  of  the  drug
combination.
united States Patent:7,157,100 to  Doshi  et al. describes a novel controlled release multilayer
composition  that  is  capable  of  delivering  a  first  active  agent  from  one  layer  immediately
followed by continuous controlled delivery of second active agent from matrix forming layer
while the dosage form floats and is retained in the fluid of the environment. The floating bilayer
system comprises of immediate release layer containing one active agent and a disintegrating
agent whereas second floating matrix forming layer comprises a gas generating component, a
gelling agent, and a second active agent. This formulation is more particularly used to control
release  of   fluoroquinolone  compositions,  which  maintain  a  therapeutically  effective  blood
concentration of fluoroquinolone for duration with once a day administration
European  Patent  no   WO2006070406  discloses  the  preparation  of  a  bilayer  tablet  of
oxacarbazepine containing one immediate release layer of drug and a sustained release layer.
This bilayer tablet maintains a therapeutically effective blood concentration of oxacarbazepine
with once a day administration.
United States Patent 5407687 to Mark D. Coffin  Alan F. Parr  discloses the formulation of a
bi-layer tablet having one layer formulated for the immediate release (IR) of ranitidine and a
second layer formulated for sustained release (SR) of ranitidine with the ratio of ranitidine in the
IR  layer  to  that  in  the  SR in  the  range  of  from about  30:70  to  about  60:40.  The  IR  layer
comprises ranitidine, filler such as lactose, matrix agents such as microcrystalline cellulose and
croscarmellose sodium, a lubricant such as magnesium stearate, and optionally other excipients
and  other  active  ingredients.  The  SR layer  comprises  ranitidine,  a  matrixing  agent  such  as
hydroypropylmethylcellulose, filler such as lactose, a lubricant such as magnesium stearate, and
optionally other excipients and other 
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U.S. Patent No. 20060251721  to Atul D et.al.  describes a Sustained release dosage forms for
twice daily oral dosing to a human patient for providing relief from pain . The sustained release
dosage form comprises an immediate release component and a sustained release component, 
2.2 Literature survey on Sustained Release Formulations
Pal  L.  T.  et  al16  designed  an  oral  sustained release  matix  tablet  of  metformin HCl  and  to
optimize the drug release profie using surface methology .Tablet  were prepared by  non aqueous
wet granulation method using HPMC K15M. A central composite design for 2 factors at 3 level
was employed to optimized drug release profile.
Reddy K. et al 17developed an  once-daily sustained-release matrix tablets of nicorandil, a novel
potassium channel opener used in cardiovascular diseases. The tablets were prepared by the wet
granulation method. Ethanolic solutions of ethylcellulose (EC), Eudragit RL-100, Eudragit RS-
100, and polyvinylpyrrolidone were used as granulating agents along with hydrophilic matrix
materials  like  hydroxypropyl  methylcellulose  (HPMC),  sodium  carboxymethylcellulose,  and
sodium alginate. The granules were evaluated for angle of repose, bulk density, compressibility
index, total porosity, and drug content. The tablets were subjected to thickness, diameter, weight
variation test, drug content, hardness, friability, and in vitro release studies. The granules showed
satisfactory  flow  properties,  compressibility,  and  drug  content.  All  the  tablet  formulations
showed acceptable pharmacotechnical properties and complied with in-house specifications for
tested parameters. According to the theoretical release profile calculation, a once daily sustained-
release formulation should release 5.92 mg of nicorandil in 1 hour, like conventional tablets, and
3.21 mg per hour up to 24 hours. The results of dissolution studies indicated that formulation F-I
(drug-to-HPMC, 1:4; ethanol as granulating agent) could extend the drug release up to 24 hours.
In  the  further  formulation  development  process,  F-IX  (drug-to-HPMC,  1:4;  EC  4%  w/v  as
granulating agent),  the  most  successful  formulation  of  the  study,  exhibited satisfactory  drug
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release in the initial hours, and the total release pattern was very close to the theoretical release
profile.  All  the  formulations  (except  F-IX)  exhibited  diffusion-dominated  drug  release.  The
mechanism of drug release from F-IX was diffusion coupled with erosion.
Satturwar P.M.  et al18. developed a controlled release of diclofenac sodium tablet using rosin
derivative  as  hydrophobic  matrix  material.  Matrix  tablets  were  prepared  by wet  granulation
method using R-1 as matrix forming material  in different  proportions and combinations. The
matrix tablets were evaluated for thickness, hardness, friability, weight variation, drug content
uniformity ans in vitro dissolution. The results suggest that the new rosin derivative (R-1) is
useful in developing sustained release matrix tablets, with drug release being prolonged for upto
10 h.R-1 thus promises considerable utility in the development of oral sustained relapse drug
delivery.
 
Patro S.S. et al 19 developed guar gum matrix tablets for oral controlled release of water-soluble
diltiazem  hydrochloride.  Matrix  tablets  of  diltiazem  hydrochloride,  using  various  viscosity
grades of guar gum in 2 proportions, were prepared by wet granulation method and subjected to
in vitro drug release studies. Diltiazem hydrochloride matrix tablets containing either 30% wt/wt
lowviscosity (LM1), 40% wt/wt medium-viscosity (MM2), or 50% wt/wt high-viscosity (HM2)
guar gum showed controlled release. The drug release from all guar gum matrix tablets followed
first-order kinetics via Fickian-diffusion. Further, the results of in vitro drug release studies in
simulated  gastrointestinal  and  colonic  fluids  showed  that  HM2  tablets  provided  controlled
release  comparable  with  marketed  sustained  release  diltiazem  hydrochloride  tablets  (D-SR
tablets). Guar gum matrix tablets HM2 showed no change in physical appearance, drug content,
or in dissolution pattern after storage at 40oC/RH 75% for 6 months. When subjected to in vivo
pharmacokinetic  evaluation  in  healthy  volunteers,  the  HM2  tablets  provided  a  slow  and
prolonged drug release when copared with D-SR tablets. Based on the results of in vitro and in
vivo studies it was concluded that that guar gum matrix tablets provided oral controlled release
of water-soluble diltiazem hydrochloride
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3. Objective and aim:
Today,  the  scenario  of  pharmaceutical  drug  delivery  is  changing  from  conventional
dosage form to new drug delivery system with main objective of patient compliance.  There are
certain  conditions  like  pain,  inflammation,  arthritis,  ankolysing  spondylitis,  seasonal  allergic
rhinitis (SAR), etc where  it is desirable to extend the dosing interval of many pharmaceuticals
while maintaining the initial plasma concentrations achievable with conventional tablets. This
would  provide  immediate  and  extended  therapeutic  effect  and  reduce  the  number  of  doses
necessary, thereby making therapy more convenient.
 Combination  formulation  of  two  or  more  active  ingredients,  are  being  designed  to
combat many clinical conditions like seasonal allergic rhinitis, cardiovascular diseases. SAR is
associated with sneezing, lachrymal and nasal secretion and nasal congestion. 
 Thus for management of these conditions patient with this  disease have to take multiple
medication for long periods of time.
This can be overcome by formulating a tablet containing two layers, one containing the
immediate  release  layer  and one containing the sustained release layer.  A bilayer  tablet  can
achieve the initial plasma concentrations achievable with conventional tablets of one drug and
maintain for long time as sustained release tablets of other drug. 
Hence the main aim of the present study is to formulate a bilayer tablet loratadine  containing an
immediate  release  layer  and  a  pseudoephedrine  HCl  as  sustained  release  layer  .The  main
objective of the present  study is  to formulate an immediate release layer  which releases  the
loratadine  quickly and  produce  antihistamine effect  which suppress  histamine induce  effect
sneezing, lachrymal and nasal secretion without sedation and sustained layer of pseudoephedrine
which produce nasal decongestion effect by using polymers in matrix such that the drug release
can be prolonged for 12 hours.
Page 19
Plan of work
4. Plan of work
1. Literature survey on the drug, polymers, technology and other excipients.
2. Preformulation studies
a. Physicochemical characterization of the drug 
b. Solubility studies of drug in different medium 
c. Interaction studies by FTIR  
d. Selection  of  suitable method for  analysis  of  drug or  development  of  standard
graph for the drug.
3. Formulation of bilayer tablets of pseudoephedrine HCl  & loratidine
4. Physical evaluation of the dosage forms 
5. In-vitro drug release studies. 
6. Kinetic of drug release studies 
7. Stability studies 
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5.DRUGS PROFILE
 5.1 Pseudoephedrine20,21,22 HCL
IUPAC Name (1S,2S)-2-methylamino-1-phenylpropan-1-olHydrochloride
Empirical formula C10H15NO,Cl
CAS 345-78-8
Molecular Weight 201.7
Table No.2: General description
Structural formula:
                     
Figure No. 4 
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Table No.3: Physical properties 
Absorption Rapid  form GIT
Onset of action Decongestant: Oral: 15-30 minutes
Metabolism: Partially hepatic
Half-life elimination 9-16 hours
Excretion Urine (70% to 90% as unchanged drug, 1% to 6% as
active norpseudoephedrine)
Duration Immediate  release  tablet:  4-6  hours;  Extended
release:12 hours
Table No.4:Pharmacodynamics /Kinetics 
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Color and Appearance white or almost white, crystalline powder
Melting range 118° -118.7°C
Solubility Freely Soluble  H2O, Freely soluble  alcohol and ether
Polymorphism Exhibits no   polymorphism
Optical rotation -61°+62.5
Pka 9.9
pH 4.5 – 6(water)
Drug Profile
Dosage:
Oral: General dosing guidelines:
Children:
<2 years: 4 mg/kg/day in divided doses every 6 hours
2-5 years: 15 mg every 4-6 hours; maximum: 60 mg/24 hours
6-12 years: 30 mg every 4-6 hours; maximum: 120 mg/24 hours
Adults: 30-60 mg every 4-6 hours, sustained release: 120 mg every 12 hours; maximum:
240 mg/24 hours.
Mode of action: 
Pseudoephedrine is a sympathomimetic amine—that is, its principal mechanism of action
relies on its indirect action on the adrenergic receptor system. While it may have weak agonist
activity at  α-  and β-adrenergic  receptors,  the principal  mechanism is to cause  the release  of
endogenous norepinephrine (noradrenaline) from storage vesicles in presynaptic neurons. The
displaced noradrenaline is  released into the neuronal  synapse where it  is  free to activate the
aforementioned postsynaptic adrenergic receptors.
These adrenergic receptors are located on the muscles lining the walls of blood vessels. When
activated  by  pseudoephedrine,  the  muscles  contract,  causing  the  blood  vessels  to  constrict
(vasoconstriction).  These  constricted  blood  vessels  now  allow less  fluid  to  leave  the  blood
vessels and enter the nose, throat and sinus linings, which results in decreased inflammation of
nasal membranes as well as decreased mucus production. 
Vasoconstriction in the nasal mucosa shrinks swollen nasal mucous membranes, reduces
tissue hyperemia, edema, and nasal congestion. Other beneficial effects may include increasing
the drainage of sinus secretions, and opening of obstructed Eustachian tubes..
Indications
Pseudoephedrine is indicated for the treatment of:
• nasal congestion 
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• sinus congestion 
• Eustachian tube congestion. 
Adverse effects
Common adverse drug reactions (ADRs) associated with pseudoephedrine therapy include: CNS
stimulation,  sleeplessness,  nervousness,  excitability,  dizziness  and  anxiety.  Infrequent  ADRs
include:  tachycardia  and/or  palpitations.  Rarely,  pseudoephedrine  therapy  may be  associated
with hallucinations, arrhythmias, hypertension, seizures and ischemic colitis; as well as severe
skin  reactions  known  as  recurrent  pseudo-scarlatina,  systemic  contact  dermatitis,  and
nonpigmenting fixed drug eruption.Pseudoephedrine, particularly in high doses, may also cause
episodes of paranoid psychosis. It has also been reported that pseudoephedrine, amongst other
sympathomimetic agents, may be associated with the occurrence of stroke.
Precautions and contraindications:
It is recommended that pseudoephedrine not be used in patients with: diabetes mellitus,
cardiovascular  disease,  hypertension,  prostatic  hypertrophy,  hyperthyroidism,  closed  angle
glaucoma  and/or  pregnancy.  Contraindications  for  the  use  of  pseudoephedrine  include:
concomitant or recent (previous fourteen days) monoamine oxidase inhibitor (MAOI) therapy,
severe or uncontrolled hypertension, and/or severe coronary artery disease.
5.2 Loratadine23,
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Molecular weight 382.9
CAS 79794-75-5
Empirical  Formula C22H23ClN2O2
IUPAC Name Ethy4-(8-chloro-5,6-dihydro-11H
benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidine)-1-
piperidinecarboxylate.
Drug Profile
          Table No.5 : General  description Table 
Structural formula:  
Figure No. 5
Color and Appearance A white to off - white, fluffy  powder
Melting range 118°C
Solubility Insoluble  in  water,  freely  soluble  acetone,  alcohol,
chloroform.
Polymorphism Exhibits no polymorphism.
Optical rotation No optical rataion
pKa value 2.5,4.0,6.7,10.1 (by aqueous acidic/basic potentiometer
titration at 25°C)
Hygroscopic nature slightly hygroscopic
Partition coefficient 10.2±0.5  in  phosphate  buffer(0.1M,pH-7)/  n-octanol
system at room temp.
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Table No.6: Physical   properties 
Onset of action 1-3 hours
Peak effect 8-12 hours
Duration >24 hours
Absorption Rapid
Metabolism Extensively  hepatic  via  CYP2D6  and  3A4  to  active
metabolite
Half-life elimination 12-15 hours
Excretion Urine (40%) and feces (40%) as metabolites
BCS class II
Binding 98%bound to Plasma Protein
Metabolite Desloratadine( 12-24 hours)
Table No.7:Pharmacokinetics / Pharmacodynamics 
Parameters LOR
Cmax 17±14/µg-L-1
Tmax
1.2±0.6 h
T1/2
6±4 h
Table No.8 Pharmacokinetic parameters of loratadine after a single oral dose of 20 mg 
 Indications
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 Loratadine is indicated for the symptomatic relief of allergy such as hay fever (allergic
rhinitis), urticaria (hives), and other skin allergies.For allergic rhinitis (hay fever), loratadine is
effective for both nasal and eye symptoms: sneezing, runny nose, itchy or burning eyes.
 Mechanism of action:
 Loratadine  is  a  tricyclic  antihistamine,  which  selectively  antagonizes  peripheral
histamine  H1-receptors.Loratadine  has  a  long-lasting  effect  and  does  not  normally  cause
drowsiness because it does not readily enter the central nervous system.
 Side-effects
Non-sedating  antihistamine  as  a  non-sedating  antihistamine,  loratadine  causes  less
sedation and psychomotor impairment than the older antihistamines because it  penetrates  the
blood brain barrier only to slight extent.Although drowsiness is rare, patients should nevertheless
be advised that it can occur and may affect performance of skilled tasks (e.g. driving); excess
alcohol should be avoided.
Most common side-effects 
Drowsiness,  headache,  psychomotor  impairment,  and  antimuscarinic  effects  such  as
urinary  retention,  dry  mouth,  blurred  vision,  and  gastrointestinal  disturbances  are  the  most
common side effects.
 Dosage
Oral: Seasonal allergic rhinitis, chronic idiopathic urticaria: 
Children 2-5 years: 5 mg once daily 
Children :6 years and Adults: 10 mg once daily 
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 Cautions and contraindications
Loratadine should be used with caution in hepatic disease and dose reduction may be
necessary in renal impairment. Caution may be required in epilepsy. Children and the elderly are
more  susceptible  to  side-effects.  Loratadine  is  a  category  L-2  (classified  by  the  American
Academy of Pediatrics as a drug "Usually Compatible with Breast-feeding and category B in
pregnancy.
                                                      LACTOSE MONOHYDRATE24
Applications in pharmaceutical formulation: Lactose is widely used as a filler or diluent in 
tablets and
capsules, and to a more limited extent in lyophilized products
and infant formulas.(1–13) Lactose is also used as a diluent in drypowder inhalation..
Incompatabilities: Lactose is also incompatible with amino acids, aminophylline,(
19) amfetamines,(20) and lisinopril.
Safty: Lactose is widely used in pharmaceutical formulations as a filler
and filler-binder in oral capsule and tablet formulations. It may
also be used in intravenous injections.
        
                            Sodium lauryl sulfate25
  
synonyms
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Dodecyl alcohol hydrogen sulfate, sodium salt, dodecyl sodiumsulfate, dodecylsulfate 
sodium salt, lauryl sodium sulfate, lauryl sulfate, sodium salt, monododecyl sodium 
sulfate, sodium dodecyl sulfate, sodium laurilsulfate, sodium monododecyl sulfate, sodium
monolauryl sulfate, SDS, SLS, sulfuric acid monododecyl ester, sodium salt, Texapon 
K12P.
Description
Sodium lauryl sulfate consists of white colored crystals, flakes, or powder having a smooth
feel, a soapy, bitter taste, and a faint odor of fatty substances. 
Functional category 
Anionic surfactant, detergent, emulsifying agent, skin penetrant, and wetting agent.
Applications in pharmaceutical formulation
1. Sodium  lauryl  sulfate  is  an  anionic  surfactant  used  in  nonparenteral  pharmaceutical
formulations and cosmetics. 
2. sodium lauryl sulfate is a detergent and wetting agent effective in both alkaline and acidic
conditions.
Stability and storage conditions
Sodium lauryl sulfate is stable in normal storage conditions. Sodium lauryl sulfate in 
solutions, at pH 2.5 or below, undergoes hydrolysis to lauryl alcohol and sodium bisulfate. stored
in a well closed container in a cool, dry place.
Incompatibilities
Sodium lauryl sulfate reacts with cationic surfactants, results in loss of activity. Sodium
lauryl sulfate is incompatible with salts of metal ions, such as aluminum, lead, tin or zinc, and
precipitates with potassium salts. Solutions of sodium lauryl sulfate (pH 9.5–10.0) are corrosive
to steel, copper, brass, bronze, and aluminum. 
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Safety
Sodium lauryl  sulfate is a moderately toxic material with acute toxic effects including
irritation to the skin, eyes, mucous membranes, upper respiratory tract, and stomach Repeated,
prolonged exposure to dilute solutions may cause drying and cracking of the skin. 
Microcrystalline Cellulose26
Synonyms
Avicel, Cellets, Celex, cellulose gel, hellulosum,  microcristallinum, Celphere, Ceolus KG,
crystalline cellulose, E460, Emcocel, Ethispheres, Fibrocel, Pharmacel, Tabulose, Vivapur.
Description
Microcrystalline cellulose is a white, odorless, tasteless, crystalline powder.
Functional category 
Adsorbent, suspending agent, Tablet and capsule diluent, 
Applications in pharmaceutical formulation
1. Microcrystalline cellulose is used as a binder, diluent in oral tablet and    capsule 
formulations.
2. Microcrystalline cellulose also has lubricant and disintegrant properties
Stability and Storage Conditions
Microcrystalline cellulose is hygroscopic material. Stored in well closed container and
protect from moisture.
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Incompatibilities
Microcrystalline cellulose is incompatible with strong Oxidizing agent.
Safety
  Microcrystalline cellulose is nontoxic and nonirritant material.
 MAGNESIUM STEARATE27.
Non-proprietary names - BP: Magnesium stearate, JP: Magnesium stearate, PhEur: Magnesii
stearas.
Synonyms  -  Magnesium  octadecanoate;  octadecanoic  acid,  magnesium  salt;  stearic  acid,
magnesium salt.
Chemical Name - Octadecanoic acid magnesium salt.
Empirical Formula and Molecular Weight - C36H70MgO4 and 591.34.
Description - The USPNF 23 describes magnesium stearate as a compound of magnesium with a
mixture of solid organic acids that consists chiefly of variable proportions of magnesium stearate
and magnesium palmitate (C32H62MgO4). The PhEur 2005 describes magnesium stearate  as a
mixture of magnesium salts of different fatty acids consisting mainly of stearic acid and palmitic
acid and in minor proportions other fatty acids. 
Structural Formula - [CH3 (CH2)16COO]2Mg.
Functional Category - Tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology - Magnesium stearate is widely used
in  cosmetics,  foods  and  pharmaceutical  formulations.  It  is  primarily  used  as  a  lubricant  in
capsule and tablet manufacture at concentrations between 0.25 and 5.0% w/w. It is also used in
barrier creams. Description magnesium stearate is a very fine, light white, precipitated or milled,
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impalpable powder of low bulk density, having a faint odor of stearic acid and a characteristic
taste. The powder is greasy to the touch and readily adheres to the skin.
Crystalline forms - high-purity magnesium stearate has been isolated as a trihydrate, a dihydrate
and an anhydrate.
Density (bulk):      0.159 gm/cm3.
Density (tapped):  0.286 gm/cm3.
Density (true):      1.092 gm/cm3.
Flash point: 250°C.
Flow ability:  poorly flowing, cohesive powder.
Melting range: 117–150°C (Commercial samples),
126–130C  (High purity magnesium stearate).
Solubility - Practically insoluble in ethanol, ethano
                                         TALC28
Synonyms : Luzenac Pharma; magnesium hydrogen
metasilicate; Magsil Osmanthus; Magsil Star; powdered talc;
Description: Talc is a very fine, white to grayish-white, odorless, impalpable,
unctuous, crystalline powder. It adheres readily to the skin and
is soft to the touch and free from grittiness.
Category: Anticaking agent; glidant; tablet and capsule diluent; tablet
Aplications in pharmaceutical formulation: Talc was once widely used in oral solid dosage 
formulations as
a lubricant and diluent, see Table I,(1–3) although today it is less
commonly used. However, it is widely used as a dissolution
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retardant in the development of controlled-release profile
Incompatibilities:
Incompatible with quaternary ammonium compounds.
ISOPROPYL ALCOHOL29.
Non-proprietary names - BP: Isopropyl alcohol, JP: Isopropanol, PhEur: Isopropyl alcohol,
USP: Isopropyl alcohol.
Synonyms -Alcohol isopropylicus,  dimethyl  carbinol,  IPA, isopropanol, petrohol, 2-propanol,
sec-propyl alcohol and rubbing alcohol.
 Empirical Formula and Molecular Weight - C3H8O and 60.1.
 Functional Category - Disinfectant and solvent.
Applications in Pharmaceutical Formulation or Technology -Isopropyl alcohol (propan-2-
ol) is  used  in  cosmetics  and  pharmaceutical  formulations,  primarily  as  a  solvent  in  topical
formulations. It  is not recommended for oral use owing to its toxicity;  although it is used in
lotions,  the  marked  degreasing  properties  of  isopropyl  alcohol  may  limit  its  usefulness  in
preparations used repeatedly.  Isopropyl  alcohol is also used as a solvent both for tablet film-
coating and for tablet granulation,(2) where the isopropyl alcohol is subsequently removed by
evaporation. It has also been shown to significantly increase the skin permeability of nimesulide
from  carbomer.  Isopropyl  alcohol  has  some  antimicrobial  activity  and  a  70%  v/v  aqueous
solution is used as a topical disinfectant. Therapeutically, isopropyl alcohol has been investigated
for the treatment of postoperative nausea or vomiting.
Typical Properties - Antimicrobial activity Isopropyl alcohol is bactericidal; at concentrations
greater than 70% v/v it is a more effective antibacterial preservative than ethanol (95%). The
bactericidal effect of aqueous solutions increases steadily as the concentration approaches 100%
v/v. Isopropyl alcohol is ineffective against bacterial spores.
Autoignition temperature is 425°C. Boiling point 82.4°C. Dielectric constant D20 = 18.62.
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Explosive limits  2.5–12.0% v/v in  air.  Flammability Flammable:  Flash  point  11.7°C (closed
cup), 138°C (open cup). The water azeotrope has a flash point of 16°C.
Melting point - 88.5°C. Moisture content is 0.1–13% w/w for commercial grades (13% w/w
corresponds  to  the  water  azeotrope).  Solubility:  Miscible  with  benzene,  chloroform,  ethanol
(95%), ether, glycerin and water. Soluble in acetone and insoluble in salt.
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6. POLYMERS PROFILE
6.1 HPMC30
1. Synonyms
Benecel MHPC;  Cellulose,  hydroxypropyl  methyl  ether;  E464;  HPMC;  Methocel;
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; Pharmacoat.
2. Chemical Name and CAS Registry Number
Cellulose, 2-Hydroxypropyl methyl ether [9004-65-3]
3. Empirical Formula       Molecular Weight
The PhEur describes hydroxypropyl methylcellulose as a partly O-methylated and O-(2-
hydroxypropylated) cellulose. 
Hydroxypropyl  methylcellulose  defined  in  the USP specifies  the  substitution type  by
appending a four digit number to the nonproprietary name, e.g., hydroxypropyl methylcellulose
1828. The first two digits refer to the approximate percentage content of the methoxy group
(OCH3).  The  second  two  digits  refer  to  the  approximate  percentage  content  of  the
hydroxypropoxy group (OCH2CHOHCH3), calculated on a dried basis. 
1. Structural Formula
Figure No.  6
    Where R is H, CH3, or [CH3 CH(OH)CH2].
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5. Functional Category
Coating agent,  film-former,  rate-controlling,  polymer  for  sustained release,  stabilizing
agent, suspending agent, tablet binder, viscosity-increasing agent.
6. Applications in Pharmaceutical Formulation or Technology
Hydroxypropyl  methylcellulose  is  widely  used  in  oral  and  topical  pharmaceutical
formulations.In  oral  products;  hydroxypropyl  methylcellulose  is  primarily  used  as  a  tablet
binder, in film-coating and as an extended-release tablet matrix. Concentrations of between 2-5%
w/w may be used as a binder in either wet- or dry-granulation processes. High viscosity grades
may be used to retard the release of drugs from a matrix at levels 10-80% w/w in tablets and
capsules.
In  addition,  hydroxypropyl  methylcellulose  is  used  in  the  manufacture  of  capsules,  as  an
adhesive in plastic bandages and as a wetting agent for hard contact lenses. It is also widely used
in cosmetics and food products.
7. Description
Hydroxypropyl  methylcellulose  is  an  odorless  and  tasteless,  white  or  creamy-white
colored fibrous or granular powder..
8. Typical Properties
Acidity/alkalinity:
pH = 5.5-8.0 for a 1% w/w aqueous solution.
Ash: 1.5-3.0%, depending upon the grade.
Autoignition temperature: 360°C
Density (bulk): 0.341 g/cm3
Density (tapped): 0.557 g/cm3
Density (true): 1.326 g/cm3
Melting  point:  Browns  at  190-200°C;  chars  at  225-230°C.  Glass  transition
temperature is 170-180°C.
Specific gravity: 1.26
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9. Stability and Storage Conditions
Hydroxypropyl  methylcellulose powder is  a stable material  although it is hygroscopic
after drying.
Hydroxypropyl methylcellulose powder should be stored in a well-closed container, in a cool,
dry, place.
10. Incompatibilities
Hydroxypropyl methylcellulose is incompatible with some oxidizing agents. Since it is
nonionic, hydroxypropyl methylcellulose will not complex with metallic salts or ionic organics
to form insoluble precipitates.
11. Safety
Hydroxypropyl  methylcellulose  is  widely  used  as  an  excipient  in  oral  and  topical
pharmaceutical formulations. It is also used extensively in cosmetics and food products.
Hydroxypropyl  methylcellulose  is  generally  regarded  as  a  nontoxic  and  nonirritant  material
although excessive oral consumption may have a laxative effect. 
12. Handling Precautions
Observe normal precautions appropriate to the circumstances  and quantity of material
handled. Hydroxypropyl methylcellulose dust may be irritant to the eyes and eye protection is
recommended. Excessive dust generation should be avoided to minimize the risks of explosions.
Hydroxypropyl methylcellulose is combustible.
6.2 Ethylcellulose (Ethocel med 50)31
1. Synonyms :Aquacoat ECD; Aqualon; E462; Ethocel; Surelease.
2. Chemical Name and CAS Registry: NumberCellulose ethyl ether [9004-57-3]
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3.  Empirical  Formula  and  Molecular  Weight:  Ethylcellulose  with  complete  ethoxyl
substitution (DS = 3) is C12H23O6(C12H22O5)nC12H23O5 where n can vary to provide a wide
variety of molecular weights. Ethylcellulose, an ethyl  ether of cellulose, is a long-chain
polymer of β-anhydroglucose units joined together by acetal linkages.
4. Structural Formula:
                           
 Figure No. 7
2. Functional Category
Coating  agent;  flavoring  fixative;  tablet  binder;  tablet
filler; viscosity-increasing agent.
Use Concentration (%)
Microencapsulation 10.0–20.0
Sustained-release tablet coating 3.0–20.0
Tablet coating 1.0–3.0
Tablet granulation 1.0–3.0
TableNo.9: Applications of HPMC in pharmaceutical formulation or technology 
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In  tablet  formulations,  ethylcellulose  may  additionally  be  employed  as  a  binder,  the
ethylcellulose being blended dry or wet-granulated with a solvent such as ethanol (95%).
Ethylcellulose produces hard tablets with low friability,  although they may demonstrate
poor dissolution.
6. Description
Ethylcellulose is a tasteless, free-flowing, white to light tan-colored powder
7. Stability and Storage Conditions
Ethylcellulose  is  a  stable,  slightly  hygroscopic  material.  It  is  chemically  resistant  to
alkalis, both dilute and concentrated, and to salt solutions, although it is more sensitive to acidic
materials  than  are  cellulose  esters.Ethylcellulose  is  subject  to  oxidative  degradation  in  the
presence of sunlight or UV light at elevated temperatures. This may be prevented by the use of
antioxidant and chemical additives that absorb light in the 230–340 nm range.
8. Incompatibilities
Incompatible with paraffin wax and microcrystalline wax.
Grade
Solution  viscosity
(mPa s)
Mean particle size (µm)
Ethocel Std 45P Premium 41.0–49.0 —
N-50 40.0–52.0 —
N-100 80.0–105.0 —
Ethocel Std 100FP Premium 90.0–110.0 30.0–60.0
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Grade
Solution  viscosity
(mPa s)
Mean particle size (µm)
Ethocel Std 45P Premium 41.0–49.0 —
Ethocel Std 100P Premium 90.0–110.0 465.0
Ethocel med 50 55.0-60 262
Table No. 10: Ethylcellulose grades,, viscosity, and particle size 
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7.1 Materials:
S. No. Excipient Category
1 Loratadine API
2 Corn Starch Diluent
3 LactoseMonohydrate Diluent and binder
4 Microcrystalline Cellulose (Avicel PH 102) Diluent
5 Aerosil Binder
6 Sodium lauryl sulfate Wetting agent 
7 Magnesium Stearate Lubricant
8 Sunset yellow colour Color
9 Talc Glident
Table No.11: Materials for immediate release layer ( Loratadine) 
S. No. Excipient Category
1 Pseudoephedrine HCl API
2 HPMC K100M Hydrophilic polymer
3 Ethyl cellulose Polymer ,binder
4 Dicalcium phosphate dihydrate Diluent
5 Colloidal Silicon Dioxide (Aerosil-200) Glidant
6 Polyvinylpyrollidone [PVP K30]) Binder
7 Talc Glidant
8 Isopropyl alcohol IP Vehicle 
9 Magnesium stearate Lubricant
          Table No. 12: Materials  for sustained release  (Pseudoephedrine HCl layer) 
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7.2 Equipments used in formulation development
S.No Equipment Manufacturer
1. Electronic Weighing Balance
Electrolab
2. Rapid mixer granulator(2.0L) Bacto chem. Pvt. Ltd.
3. Rapid dryer Retsch
4. Multi mill SSPM  Pvt. Ltd.
5. Compression machine Karanavathi 
6. Induction cap sealer Electronic devices
7. Hardness tester Schleniger pharmaton
8.
Friabilator Electrolab
9. Disintegration test apparatus Electrolab
10. Dissolution apparatus Electrolab
11.
Halogen moisture analyser Mettler Toledo
12.
Bulk density apparatus Electrolab
13.
Sieve Shaker Retsch
14. Mechanical sifter SSPM  Pvt. Ltd.
15. HPLC Waters
Table no: 13 Equipments used in formulation development
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8. Preformulation Study32:
Preformulation testing is the first  step in the rational  development of dosage form of a drug
substance. It can be defined as an investigation of physical and chemical properties of a drug
substance  alone and when combined with excipient.  The overall  objective of  preformulation
testing is to generate information useful to the formulator in developing stable and bioavailability
dosage forms that can be mass produced.
                   Following the identification of a  new chemical  entity that  is  suitable for
development,  the formulator  will  be  called  upon to  produce  dosage  form.  Initially  this  may
involve  production  of  Injectable  form  suitable  for  early  efficiency  and  toxicity  testing  and
subsequently there with be a need to develop the final dosage form which generally with not be
Injectable. The challenge for the formulator is to develop the initial and final dosage form to the
highest  quality in  shortest  time. This process  is  best  achieved  when certain  physicochemical
properties  of  the  drug  substance  are  investigated  understood  and  effectively  utilized;  this  is
preformulation.
Need of preformulation studies 
Scientific and regulatory justification of acquiring Preformulation data includes the following.
1) Establishment  of  drug  specification  intended  for  toxicological  evaluation  and  clinical
supply preparation. 
2) Formulation of clinical supplies and establishment of their preliminary specification.
3) Providing scientific data to support dosage form development and evaluation of product
efficacy, quality, stability and bioavailability.
4) Evaluation of the stability of early developed dosage forms.
5) Fulfillment of the requirement of the Chemistry Manufacturing Control  section of the
Investigational  New Drug23 (IND)  and  subsequent  New  Drug  Application  (NDA)  or
Abbreviated New Drug Application (AND). 
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8.1   Preformulation study can divided into two subclasses33.
1) Active pharmaceutical ingredient (API) characterization:
Organoleptic evaluation 
These  are  preliminary  characteristics  of  any  substance,  which  is  useful  in  identification  of
specific material. Following physical properties of   API were studied.
• Color
•  Taste
•   Odor
2) Compatibility study 
The  compatibility  of  drug  and  formulation  components is  an  important  prerequisite
before formulation. It  is therefore necessary to confirm that the drug does not react  with the
polymers and excipients under experimental conditions and affect the shelf life of product or any
other unwanted effects on the formulation.
8.2 Preformulation studies include investigation of 
I. Bulk characterization 
a. Crystallinity and polymorphism 
b. Hygroscopicity 
c. Fine particle characterization 
d. Bulk density
e. Powder flow properties 
II. Solubility analysis
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a. Ionization constant – pKa
b. pH solubility profile 
c. Common ion effect 
d. Thermal effect 
e. Solubilization 
f. Partition coefficient 
g. Dissolution
III. Stability analysis 
• Solid state stability of drug alone 
• Stability in presence of excipient (Compatibility studies)
• Solution  phase  stability  (Stability  in  gastrointestinal  fluid  and  granulating
solvents)
IV. Photo stability studies
 (1) Evaluation of physical properties of drug (Bulk characterization)
1. Angle of repose  
Flowability24 of mixture was determined by calculating angle of repose by fixed height method.
A funnel with 10 mm diameter of stem was fixed at a height of 2 cm. over the platform. About
10 gm of sample was slowly passed along the wall of the funnel till the tip of the pile formed and
touches the stem of the funnel. A rough circle was drawn around the pile base and the radius of
the powder cone was measured. Angle of repose was calculated from the average radius using
the following formula.                           
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Table No.11: Flow Characteristics 
θ = tan−1 (h/r)
Where,
θ = Angle of repose.
h = Height of the pile.
r = Average radius of the powder cone
API Height(Cm) Radius(Cm
)
Angle of repose(θ ) Flow
Characteristics
Pseusdoephedrine 2.9 4.0 35.94
o Passable
Loratadine Very fine powder Very poor
           Table No. 14: Results of angle of repose (θ) and flow characteristics of API’S
2. Bulk density  
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Angle of repose Flow characteristics
<25 Excellent
25-30 Good
30-40 Passable
>40 Very Poor
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Bulk densities of all types of mixture were determined by pouring gently 10 gm of
sample through a glass funnel into a 100 ml graduated cylinder. The volume occupied by the
sample was recorded. Bulk density was calculated.
Bulk density (g/ml) = sample theby  accupied Volume
 sample of Weight
API Bulk Density (gm/ml)
Pseudoephedrine 0.601
Loratadine 0.199
                                      Table No. 15: Results of bulk density of API’S
3. Tapped density 
Tapped density was determined by using electro lab density tester, which consists of a graduated
cylinder mounted on a mechanical tapping device. An accurately weighed sample of powder was
carefully added to the cylinder with the aid of a funnel. Typically, the initial volume was noted,
and the sample is then tapped (50 tapping) until no further reduction in volume is noted or the
percentage of difference is not more than 2%.
A sufficient number of taps should be employed to assure reproducibility for the material
in question. Volume was noted and taped density is calculated using following formula.
Tapped density [g/ml] =  sample theby  accupied Volume
 sample of Weight
API Tapped Density (gm/ml)
Pseudoephedrine 0.683
Loratadine 0.293
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Table No.16: Results of tapped density of API’s
4. Compressibility (%):
It  is  also one of  the sample methods to evaluate flow property of  a powder by
comparing the bulk density and tapped density. A useful empirical guide in given by the Carr’s
compressibility. 
Carr’s Index = 100
density  Tapped
density Bulk density  Tapped
×
−
API Bulk
Density
Tapped
Density
Compressibility
index (%)
Pseusdoephedrine 0.544 0.683
12.00
Loratadine 0.601 0.293
31.43
  Table No. 17: Results of compressibility (%) of API’s
Table No.18: Relationship of flow character with compressibility index (%) 
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Index (%)
Flow
Character
<10 Excellent
11–15 Good
16–20 Fair
21–25 Passable
26–31 Poor
32–37 Very poor
>38 Very, very poor
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5. Hausner ratio: 
It  provides  an indication of the degree of densification which could result  from
vibration of feed hopper 
Hausner ratio =  
densityBulk 
density   Tapped
<1.2 =Free Flowing                        
  1.2-1.8 =Cohesive                 
 Table No.19: Results of flow characteristics Hausner’s ratio of API’s    
6. Sieve Analysis34 
               The main aim of analysis is to determine the different size of drug particles present. A series of
standard sieves were stacked one over the above so that sieves with larger pore size (Less Sieve
No) occupy top position followed by a series of decreasing pore size (Larger Sieve No) towards
the bottom.
               Procedure:  The procedure involves the Electromagnetic Sieve shaking of the sample through
the    series  of  successively  arranged  sieves  (sieve  no.  -  20,30,60,80,100  and  receiver),  and
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API Bulk
Density
Tapped
Density
Hausner
ratio
Flow
Characteristics
Pseusdoephedrine 0.544 0.683 1.136 Free flowing
Loratadine 0.601 0.293 1.472 Cohesive
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weighing of the portion of the sample retained on each sieve and calculate percentage retained on
each sieve.
50gram of both blend of pseudoephedrine HCl electromagnetic sieve shaking and weighing of
the portion of the sample retained on each sieve and calculates percentage retained on each sieve.
 
  
      Table No. 20: Sieve analysis observation of pseudoephedrine HCl
7. Loss on drying: 
Loss  on drying is  the loss of weight  expressed as  percentage  w/w resulting from water  and
volatile matter of any kind that can be driven off under specified conditions the test is carried on
a well mixed sample of the substance. If the substance is the form of large crystals reduce the
size by rapid crushing to a powder.
B.Method II: 
0.5g of sample of pseudoephedrine & loratadine blend was accurately weighed and the powder
was  kept  in  a  Mettler  Toledo  apparatus  for  5  min.  at  105ºC and  the  moisture  content  was
calculated.
API L.O.D.
Peudoephedrine 0.42%
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Sieve No. Used Pore Size in
µm
% Retained Cumulative %
Retained
20 850 0 0
30 600 4.94 4.94
60 250 70.7 75.64
80 180 12.4 88.04
100 150 10.2 98.24
BASE NA 1.76 100
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Loratadine 0.37%
  Table No.21:  Loss on drying results of API’s
 (2) Solubility Analysis35:
1. Drug pKa & pH:
 The amount of drug that exists in unionized form is a function of dissociation constant (pKa) of
the drug it is customary to express the dissociation constants of both acidic and basic drugs by
pKa values. Lower the pKa of an acidic drug stronger  the acid i.e. greater  the proportion of
ionized form at a particular pH. The higher the pKa of basic drug, the stronger the base. Thus
from the knowledge of pKa of the drug and ph at absorption site (or biological fluid).the relative
amount of ionized and unionized drug in solution at a particular pH and the percent of drug
ionized at this ph can be determined by Henderson-hasselbach equation 
For Weak acids: pH=pKa+ log ionconcentrat drug unionized
ion  concentrat drug ionized
% Drug Ionized    =             10  pH-pKa       × 100
                                       1+10pH-pKa    
For weak base:    pH=pKa+ log ionconcentrat drug ionized
ion  concentrat drug unionized
                     
% Drug Ionized       =                    10  pKa-pH       × 100
                                                 1+10pKa-pH
For weak Acids:
1. Very weak acids (pKa>8) such as phenytoin and several barbiturates are essentially unionized
at all pH values and therefore their absorption is rapid and independent of GI pH
2. Acids in pKa range 2.5 to 7.5 are generally affected by changes in ph and therefore their
absorption is pH dependent e.g. several NSAIDS like aspirin, ibuprofen are better absorbed from
acidic condition of stomach
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3. Stronger acids with (pKa<2.5) such as cromolyn sodium are ionized in the entire pH range of
GIT and therefore remain poorly absorbed
For Weak base:
1.  Very  weak  base  (pKa<5)  such  as  caffeine,  theophylline,  carboxylic  acid  derivatives  are
essentially unionized at all pH values and therefore their absorption is rapid and pH independent
2. Bases  in the pKa range 5 to 11.0 are generally affected by change in pH and hence their
absorption  is  pH-dependent.  Such  drug  are  better  absorbed  from  the  relatively  alkaline
conditions of the intestines where they are largely exist in unionized form
3. Stronger Bases with pKa> 11.0 like mecamylamine are ionized in the entire pH range of GIT0
and therefore poorly absorbed.
Effect of  pH  on the Absorption of pseudoephedrine Drug 
pKa of pseudoephedrine Drug~9.9 therefore their absorption is rapid and independent of
GI pH
Effect of pH on absorption of loratadine drug:
pKa of  loratadine is~4.2(Moderately weak acid)
pH % Drug
Ionized
% Drug
unionized
Absorption
1.0 0.31% 99.69% Absorbed rapidly
3.2 66.61% 33.40% Absorbed rapidly
4.2 83.378 17.73% Absorption decreases
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5.2 98.043 1.96% Poor Absorption
7.5 99.990 0.11% Very poor Absorption
Table No.22: Effect of pH on the absorption of loratadine
Figure No. 8
2. pH solubility profile 
It is recommended that the pH-solubility profile of the test drug substance should be determined
at 37 ±1 0C in aqueous media with a ph in the range of 1.0-7.5. According to the FDA Guidance,
the  number  of  pH conditions  for  a  solubility  determination  can  be  based  on  the  ionization
characteristics of the test drug substance. When the pKa value of drug is in the range of 3-5, the
solubility should be determined at pH=pKa, pH=pKa+1, pH=pKa-1 and at pH = 1.0 and 7.5.
Pseudoephedrine has a pKa of 9.9 and loratadine has a pKa of 4.4. Therefore, the solubility of
pseudoephedrine and loratadine was determined in 0.1N HCl , D.M. water , 4.5 pH acetate buffer
, 5.5 pH acetate buffer & 6.8 pH phosphate buffer . Experimental results showed that aspirin has
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a pH dependent solubility. Solubility of aspirin increases when the pH of the medium increased
from 1.0 to 7.5.  
pH, pKa and solubility: Solubility is influenced by the degree of ionization of the  substance.
Total aqueous solubility of an ionizable substance can be expressed as: 
ST = [HA] + [A-] for a weak acid 
ST = [B] + [BH+] for a weak base 
Or ST = SHA + [A-] for a weak acid 
ST = ST + [BH+] for a weak base 
Where ST is the total solubility and SHA and SB are the solubilities of the unionized weak acid
or weak base. 
For a non-ionizable substance, a non-electrolyte: 
ST = SNE 
For a weak acid, the following equation can be derived: 
ST = SHA + KaSHA / [H3O+]
Which indicates that solubility of a weak acid increase with increasing ph (decreasing H3O+
concentration) so as ↑ pH then ↓HA, ↑A-, and ↑ST? 
Correlation  with  Henderson  Hasselbach:  Maximum  aqueous  solubility  for  weak  acids  is
attained at pH-pKa » 2, where 99% is in the ionized (A-) form. Minimum solubility is at pH-pKa
» -2 where 99% is in the unionized (HA) form. The logarithmic form can be used to predict the
pH (pHp) below which the unionized weak acid would precipitate from solution: 
pHp = pKa + log ST-SHA / SHA 
Descriptive term Part of solvent required for 1 part
of solute
Very soluble Less than 1
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Freely soluble From 1 to 10
Soluble From 10 to 30
Sparingly soluble From 30 to 100
Slightly soluble From 100 to1000
Very slightly soluble From 1000 to 10,000
Practically insoluble 10,000 and over
Table No. 23: Relative terms of solubility
Medium Used Solubility in mg /ml
0.1N HCl 455.86
D.M. water 583.76
4.5 pH acetate buffer 569.50
5.5 pH acetate buffer 569.361
6.8 pH phosphate buffer 574.76
   Table No. 24: Effect of pH on solubility of the pseudoephedrine HCl drug 
For a weak base, the following equation can be derived: 
ST = SB + [H3O+] SB / Ka   
Which indicates  that  solubility of weak base increases  with decreasing ph (increasing H3O+
concentration) so as the ↓ ph then the ↓B, ↑BH+, and ↑ST? 
Correlation  with  Henderson  Hasselbach: Maximum aqueous  solubility  for  weak  bases  is
attained at pH-pKa » -2, where 99% is in the ionized (BH+) form. Minimum solubility is at pH-
pKa » 2 where 99% is in the unionized (B) form. 
The logarithmic form can be used to predict the pH (pHp) above which the weak base would
precipitate from solution: 
pHp = pKa + log SB / ST-SB 
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Solubility of weak acids and weak bases in buffers vs. water: 
• The solubilities of a weak acid and its conjugate base are identical in a buffer solution. The pH
of the buffer solution determines the B/A ratio and the solubility will be the same for either form
(weak acid or conjugate base). The same is true for a weak base and its conjugate acid. 
•  The solubilities of a weak acid and its conjugate base are different in water. Addition of the
weak acid makes the water acidic so there is more of the unionized weak acid form present and
solubility is low. Addition of the conjugate base makes the water basic so there is more of the
ionized form present and solubility is high. 
• The solubilities of a weak base and its conjugate acid are also different in water for a similar
reason. Addition of the weak base makes the water basic so there is more of the unionized weak
base form present and solubility is low. Addition of the conjugate acid makes the water acidic so
there is more of the ionized form present and solubility is high. 
Used Medium Solubility(mg /ml)
0.1N HCl 35.66
D.M.  water 0.6
4.5 ph acetate buffer 4.44
5.5 pH acetate buffer 0
6.8 pH phosphate buffer 0
  Table No. 25: Effect of pH on the solubility of loratadine drug 
(2)  Drug excipient compatibility (Stability in presence of excipient)
A drug  or  active  principle  is  most  often  delivered  to  patient  along  with  other
chemical  substance  within  a  pharmaceutical  formulation,  which  should  comply  with  strict
specification, often prescribed by law. In order to be approved a formulation should warrant well
defined level of stability safely and efficacy. The desired level of stability is often difficult to
achieve because the active principle may interact with the other substances of the formulation,
the so called excipient which do not have a specific pharmaceutical activity.Owning to the length
and complexity of  the approval  process,  it  is  of  paramount  importance  to  address  the drug-
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Excipient.  Compatibility  issue  from  the  early  stage  of  Preformulation.  The  standard  “Fast
stability test”  involves storing binary drug-Excipient  mixture under  extreme temperature  and
humidity condition and periodically determining the drug concentration Possible pitfall of this
test is that concentration dependent effect are usually not identified, while some of the reaction
observed at high temperature / humidity may not occur in normal stage storage.
Need of drug excipient compatibility study.
        1.) To provide the information to the formulator this will help to select the excipient for
formulation of dosage form 
2)  To  check  whether  the  stability  is  ascertain  during  the  toxicological  study  during  the
toxicological study. 
 3) To check the shelf life of drug in presence of excipients.
4) To check the loss of pharmaceutical elegance (fading of colored solution and tablets).
5) To check the bioavailability in presence of different excipients. 
6) To check the loss of active ingredient.
In this study the excipients were selected which are generally used in tablets formulation
Ratio  of  drug vs.  excipient  is  taken as  per  their  concentration  in  prototype  development
formula.  To  maximize  possible  physico-chemical  interaction,  drug  and  excipients  were
mixed together into two ways as follow
 (1) Drug was mixed with excipient in Dry Form kept in a colorless and transparent vial
with rubber plug and aluminum seal.
(2) Drug was mixed with excipient in dry form then granulated with water and IPA then 
      dried these dried granules are kept in colorless and transparent vial with rubber plug
and aluminum seal. All the samples as described below were kept at  25oC, 25  oC /
60% RH,40o C, 40o C/75% RH
Incubation Conditions: 40o C/75% RH
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Intervals: 7 days, 15 days, 30 days 
Quantity: Approx 100 mg/ vial
Packing Material: USP Type-I clear and transparent glass vials of capacity 10 ml, grey
butyl rubber plugs and Aluminum seals  
S.No. Name of Excipient
Drug:
Excipient
ratio
Initial color
After
7 days
After 15
days
After
30 days
1. Corn Starch 1:1
White fine
powder
No
change
No
change
No
change
2. LactoseMonohydrate 1:1
White fine
powder
No
change
No
change
No
change
3.
Microcrystalline
Cellulose ranq
1:1
White free
flowing
granular
powder
No
change
No
change
No
change
5.
Polyvinyl Pyrrolidone
(Povidone K-30)
4:1
Light
yellowish-
white fine
powder
No
change
No
change
No
change
6.
Sodium Starch
Glycolate (Primogel)
4:1
White fine
powder
No
change
No
change.
No
change
7.
Colloidal Silicon
Dioxide (Aerosil-200)
10:1
White fluffy
free flowing
powder
No
change
No
change
No
change
8. Magnesium Stearate 10:1
White fine
powder
No
change
No
change
No
change
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9. Talc 5:1
White color
fine
powder
No
change
No
change
No
change
10 Sunset yellow Lake 10:1
Colored fine
powder
No
change
No
change
No
change
Table 26: Compatibility study of loratadine with excipients to determine change in
 Color.
    
S.
No.
Name of Excipient Drug:
Excipient
ratio
Initial color After 7
days
After 15
days
After 30
days
1. HPMC K100M 1:1 White color No change No change No change
2. Ethyl cellulose 1:1 White color No change No change No change
3. Dicalcium phosphate
dehydrate
1:1 White color free
flowing
No change No change No change
4.
Polyvinylpyrollidone
4:1 White color fine No change No change No change
5. Talc 5:1 White color fine No change No change No change
6. Colloidal SiO2 10:1 White fluffy free
flowing powder
No change No change No change
7. Magnesium stearate 10:1 White fine
powder
No change No change No change
Table No.27: Compatibility  study of  pseudoephedrine hydrochloride with excipients to determine
change in color 
8.3 Standard curve of psrudoephedrine HCl  in D.M water:
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Psrudoephedrine HCl (100 mg) was accurately weighed and dissolved in 100 ml D.M water.
Then 10 ml of this solution was  transferred to another 100 ml volumetric flask to obtain a stock
solution of 100 µg/ml. Different dilutions were prepared as per the Table. The absorbance were
taken on double beam UV spectrophotometer using λmax  257nm.The results are submit in Table
11  as Fig.8 . Similarly, this standard curve were prepared in 0.1N HCl, acetate buffer pH 7.4,
acetate buffer pH 5.5,phosphate buffer pH 6.8. 
S.No. Vol.of Stock (ml) Final Vol. (ml) Concentration (µg/ml) Absorbance
λmax (257 nm)
1. 0 100 0 0
2. 2 100 2 0.052
3. 5 100 5 0.134
4. 10 100 10 0.221
5. 15 100 15 0.345
6. 20 100 20 0.531
7. 25 100 25 0.612
8 30 100 30 0.770
Table No.28: Standard curve values of psrudoephedrine HCl
Figure No. 9
8.4 Standard curve of loratadine in 0.1 NHCl:
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Loratadine (100 mg) was accurately weighed and dissolved in 100 ml of 0.1 N HCl solution.
Then 10 ml of this solution was  transferred to another 100 ml volumetric flask to obtain a stock
solution of 100 µg/ml. Different dilutions were prepared as per the Table. The absorbance were
taken on double beam UV spectrophotometer using λmax  280nm.The results are submit in Table
12 as Fig.9.Similarly,  this standard curve were prepared in 0.1N HCl, acetate buffer pH 7.4,
acetate buffer pH 5.5,phosphate buffer pH 6.8. 
S.No. Vol.of Stock (ml) Final Vol. (ml) Concentration (µg/ml) Absorbance
λmax (280 nm) 
1. 0 100 0 0
2. 2 100 2 0.061
3. 5 100 5 0.114
4. 10 100 10 0.227
5. 15 100 15 0.350
6. 20
100
20 0.467
7. 25 100 25 0.571
8 30 100 30 0.672
Table No.27: Standard curve values of loratadine in 0.1 N HCl 
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  Figure No. 10
8.5 Analysis of innovator product
A comparative analysis of innovator product and formulator product helps in calculation
of the (f1) dissimilarity & (f2) similarity dissolution factor. Analysis of the innovator product was
carried out for various physical parameters and in-vitro dissolution profile.
Parameters: 
• Shape.
• Thickness test.
• Hardness test.
• Friability test.
• Weight Variation test.
• In-vitro dissolution studies.
• Drug content uniformity test.
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S. 
No.
Physical
appearance
Weight
(mg)
Thickness
(mm)
Hardness
(Kg/cm2)
D.T. 
IR layer
(seconds)
Assay
%
1.
12.5mm
diameter. Two
layer one sunset
yellow and one
white
598-601 4.22±0.3 4-5
41-51
SR
98.23%
IR
102.2%
2. 599-605.3 4.02±0.1 4-3
3. 598-601.9 4.20±0.4 5-4
4. 599-601.1 4.22±0.3 5-6
5. 598-603.5 4.21±0.2 4-3
6. 599-602.1 4.20±0.3 4-3
Average 602.4 4.15 4.33
Table No.30: Analysis of innovator product data sheet
9. Experimental Work:
Materials:
S. No. Excipient Category
1 Loratadine API
2 Corn Starch Diluent
3 LactoseMonohydrate Diluent and binder
4 Microcrystalline Cellulose (Avicel PH 102) Diluent
5 Aerosil Binder
6 Sodium lauryl sulfate Wetting agent 
7 Magnesium Stearate Lubricant
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8 Sunset yellow colour Color
9 Talc Glident
Table No.31: Materials for immediate release layer ( Loratadine) 
S. No. Excipient Category
1 Pseudoephedrine HCl API
2 HPMC K100M Hydrophilic polymer
3 Ethyl cellulose Polymer ,binder
4 Dicalcium phosphate dihydrate Diluent
5 Colloidal Silicon Dioxide (Aerosil-200) Glidant
6 Polyvinylpyrollidone [PVP K30]) Binder
7 Talc Glidant
8 Isopropyl alcohol IP Vehicle 
9 Magnesium stearate Lubricant
     Table No. 32: Materials  for sustained release  (Pseudoephedrine HCl layer) 
Formulation development 
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S.
No.
Trials
Method of
Formulation
Wet
Granulation
Wet
Granulation
Wet
Granulation
Wet
Granulation
Ingredients P1 P2 P3 P4
1 Pseusdoephedrine
HCl
120 120 120 120
2 Talc 5 5 5 5
3 Magnesium
stearate
2 2 2 2
4 Colloidal silica 3 3 3 3
5 Starch 20 - -
6 PVPK 30 - 20 20 20
7 Purified Water q.s q.s - q.s
8 Isopropyl alcohol - q.s q.s
9 HPMC K100M 160 160 160 160
10 Ethyl cellulose 40 40 40 40
11 DCP Anhydrous 50 50 50 50
 Experimental work
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S.
No.
         Trials
Method of
Formulation
Direct compression Slugging Slugging Slugging
Ingredients P5 P6 P7 P8
1 Pseusdoephedrine
HCl
120 120 120 120
2 HPMC K100M 160 160 160 160
3 Ethyl cellulose 40 40 40 40
4
Colloidal silica
3 2 2 2
5
Talc
                 5 5 5 5
6
Magnesium stearate
2 2 2 2
7
PVPK-30
20 20 20 20
8
Lactose anhydrous
- 50 35 25
9 DCP anhydrous - - 15 25
10
Magnesium stearate
- 2 2 2
 Experimental work
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S.No        Trials
Method of
Formulation
Slugging Slugging Slugging Slugging Slugging
Ingredients P9 P10 P11 P12 P13
1 Pseusdoephedrine
HCl
120 120 120 120 120
2
HPMC K100M
4 4 4 4 4
3 Ethyl cellulose 2 2 2 2 2
4
Colloidal silica
2 2 2 2 2
5
Talc
5 5 5 5 5
6 Magnesium
stearate
2 2 2 2 2
7
PVPK-30
20 20 20 20 20
8 Lactose
anhydrous
- 45 15 25 -
9
DCP anhydrous
50 -
10
DCP dihydrate
- 5 35 25 50
11 Magnesium
stearate
2 2 2 2 2
 Experimental work
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S.
No.
Trials
Method of 
Formulation
   Wet
Granulation
Wet
Granulation
 Wet
Granulation
Wet
Granulation
Ingredients L1 L2 L3 L4
1
Loratadine 5 5 5 5
2 Lactose
Monohydrate 80 80 80 83.3
3
Maize Starch - 28 25 31.23
4 Color sunset
yellow Lake 0.50 0.50 0.50 0.53
5 Sodium lauryl
sulfate - - 3 -
6
Maize Starch (P) 38 10 10 5
7
Purified Water q.s q.s q.s q.s
8 Microcrystalline
Ranq 102 50 50 50 50
9 Color sunset
yellow Lake 0.50 0.50 0.50 0.540
10 Maize Starch
(Dried) 22 22 22 20
11
Aerosil 2 2 2 2
12 Magnesium
stearate 2 2 2 2.3
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Manufacturing process:
Wet granulation process steps (Loratadine) 
 1.  All excipient was weighed according to formula and passed drug and excipient by #40
sieve except magnesium stearate and color sunset yellow.
 2.  Drug and lactose was mixed dried starch and color (#60 sieve passed) and dry mixing is
done manually in polybag.  
3.  Slurry was made of starch using water as vehicle (starch: vehicle:: 1:4) and heated till
translucent paste was formed.
4.  Granules was made with help of  granulator and dry at 70o  C in FBD for till semidry
mass obtained then passed form #16 mesh sieve and then  again dry till LOD reaches at
3 to 4 % and final granules was obtained by passing it #24 sieve.
5. Granules were mixed with extra granular portion and color (#60sieve passed) for 20 min.
6.  Aerosil -200 and talcum were passed #40 sieve and mixed for 5 min.
7.  Magnesium stearate was passed form #60  sieve and mixed for 1 min. 
Direct compression process steps37 (pseudoephedrine HCl): 
1.  All excipient was weighed according to formula and passed drug and excipient by #40
sieve except magnesium stearate.
2.  Drug  and  polymers  was  mixed  thoroughly  for  10  min.  and  prepared  homogenous
mixture manually in polybag. 
3.  Other excipient was added and mixed for 20 min. 
4.  Aerosil -200 and talcum was passed through  #40  sieve and mixed for 5 min.
5.  Magnesium stearate was passed from #60 sieve and mixed for 1 min.
Dry granulation process steps (pseudoephedrine HCl):
1. All excipient was weighed according to formula and passed drug and excipient by #40
sieve except magnesium stearate.
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2.  Drug  and  polymers  was  mixed  thoroughly  for  10  min.  and  prepared  homogenous
mixture manually in polybag.
3. Other excipients was added and mixed it for 20 min.
4. Magnesium stearate was passed from #60 mesh sieve and mixed for 1 min.
5. Compressed blend using 16mm FB punch and at  weight range between 1000 to 1400 mg
and hardness between 3-4 kg/cm3
6. Tablets  passed  through  multimill  to  form  granules  and  then  passed
through #16 sieve and final passed #24 sieve.
7. Extra granular portion was added and mixed for 20 min.
8. Aerosil -200 and talcum was passed through #40 sieve and mixed for 5 min.
9. Passed magnesium stearate from #60 mesh sieve and mixed for 1 min.
Compression steps:
1) First compressed pseudoephdrine HCl layer and weight was adjusted 400mg.
2) Loratadine layer was compressed and weight was adjusted 200 mg.
3) Pseudoephedrine HCl  layer was placed on loratadine one by one and then compressed
both layer 
Trials
No.
Loss on
drying
(%w/w)
Bulk
Density
(gm/ml)
Tapped
density
(gm/ml)
Carr's
index (%)
Hauser’
s ratio
Angle of
repose
(fixed
funnel
method)I* II**
1 2.56 2.45 0.508 0.564 9.92 1.11 N.A
2 2.81 2.61 0.523 0.585 10.59 1.11 N.A
3 3.72 3.55 0.524 0.585 10.42 1.11 N.A
4 4.02 3.73 0.512 0.549 6.73 1.07 N.A
5 3.26 0.556 0.643 13.53 1.15 35.25 o
6 3.02 0.556 0.697 20.23 1.25 32.5 o
7 3.89 0.556 0.663 16.13 1.19 37.4o
8 2.89 0.559 0.682 18.03 1.22 36.7o 
9 4.50 0.587 0.693 15.29 1.18 34.46o 
10 4.56 0.573 0.687 16.59 1.19 35.73o 
11 4.05 0.563 0.695 18.97 1.23 35.75o 
12 4.25 0.578 0.687 23.56 1.18 35.35o 
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13 3.98 0.550 0.684 19.59 1.24 34.25 o
Table No.37: Pre compression parameters of Pn trials 
I* = after drying I**=after Lubrication 
Trial
No.
Loss on drying
(%w/w) Bulkdensity
(gm/ml)
Tap
density
(gm/ml)
Carr’s
index
(%)
Hauser’
s ratio
Angle of
repose
(fixed
funnel
method)I* II**
L1 2.56 2.75 0.575 0.682 20.08 1.186 35.02o
L2 2.81 3.37 0.505 0.645 21.70 1.277 34.46o
L3 2.72 3.15 0.587 0.691 15.05 1.177 34.28o
L4 2.45 3.42 0.545 0.656 16.92 1.203 32.25o
Table No. 38: Pre compression parameters of Ln trials
I* = after drying I**=after Lubrication
9. Evaluation of formulation38:
9.1 Physical evaluation:
Weight variation: 
The weight variation test is carried out in order to ensure uniformity in the weight of tablets in a
batch. The total weight of 20 tablets from each formulation was determined and the average was
calculated. The individual weights of the tablets were also determined accurately and the weight
variation was calculated .The weight variation values are tabulated in the table. 
Hardness of tablets:
The hardness of tablet is an indication of its strength. Measuring the force required to break the
tablet  across  tests  it.  The  force  is  measured  in  kg and the  hardness  of  about  4-5  kg/cm2  is
considered to be satisfactory for uncoated tablets. Hardness of 10 tablets from each formulation
Page 70
 Experimental work
was determined by Monsanto hardness tester. The hardness and standard deviation values are
tabulated in table. 
Friability test 
 Friability is the loss of weight of tablet in the container due to removal of fine particles from the
surface. Friability test is carried out to access the ability of the tablet to withstand abrasion in
packaging, handling and transport. Roche friabilator was employed for finding the friability of
the tablets. 10 tablets from each formulation were weighed and placed in Roche friabilator that
rotated at 25 rpm for 100 ratation. The tablets were dedusted and weighed again. The percentage
of weight loss was calculated again.  The percentage of weight loss was calculated using the
formula 
% friability = [(W1-W2)100]/W1
Where,
   W1= Weight of tablet before test 
    W2 = Weight of tablet after test 
The friability values are tabulated in table
Table No. 39:Post compression parameters of all trials
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Trails Average
Wt (mg)
Thickness (mm)
(Mean ± S.D.)*
Hardness 
(kg/cm2)
Friability
P1+L2 568-630 4.01±0.1 5-6 0.21
P2+L3 575-620 4.02±0.2 4-6 0.45
P3+L4 597-612 4.01±0.4 2-3 0.78
P4+L4 578-609 4.04±0.3 4-5 0.41
P5 +L4 594-609 4.02±0.2 5-6 0.12
P6 +L4 603-6016 4.01±0.3 2-3 0.65
P7 +L4 598-619 4.02±0.1 4-5 0.73
P8 +L4 586-617 3.98±0.2 2-3 0.63
P9 +L4 596-612 4.04±.03 3-4 0.53
P10 +L4 592-618 4.0±0.3 4-5 0.59
P11 +L4 594-619 4.02±0.2 2-3 0.33
P12 +L4 603-609 4.0±0.3 4-5 0.38
P13 +L4 595-608 4.0±0.2 4-5 0.36
 Experimental work
*n=3 Note wt variation present in P1, P2, P4
9.2 Assay:
The chromatographic conditions described was used.
• System :Waters 2695
• Column : A stainless steel  column 250 x4.6 mm,5µm  C18(250 cm X 4.6 mm, 5
microns)  or equivalent
• Flow rate: 1.5 ml/min,
• Mobile Phase: Acetonitrile:Water:Tri ethyl amine : :600ml:400ml:1ml
             Final adjust pH3.5 by orthophosphoric acid
• Wavelength: 254 nm,
• Injection volume: 20 µl,
• Run time: 1.5ml/min,
• Column temperature: 35oC.
Standard preparation: Standard of pseudoephedrine  hydrochloride  240mg & loratadine 10mg was
taken in 50ml volumetric flask. 25ml diluents was added and mixed. Volume was
adjusted with 50 ml of mobile phase and directly injected.
Test preparation:      20 tablets was weight and average weight was determined and the tablets were
crushed to powder. Equivalent weight to pseudoephedrine hydrochloride 240mg
& Loratadine 10 mg (two tablets)  was taken in 50 ml volumetric  flask.  25ml
diluents was added sonicated for 15 minutes. Volume was made up with 50ml
mobile phase and filtered. Filtered solution was injected directly. 
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Procedure:             Assay was carried out in HPLC (waters system) including pump, photodiode
array detector  .separately  inject  20  µl  of  the  Standard  and  the  Sample
Preparation in  to  the liquid chromatograph  and record  the area  for  the
major peak.
Calculation:                     
                    
                             
                                                      AT                    W1             100          P         
                      % of Drug  =                  x             x              x             Average weight
                                                         AS                   100        W2       100
AT=  Average  of  the  area  count  of  the Drug  peak  obtained  from  the
chromatograms of the test aliquots.
AS =Average of the area count of the Drug peak obtained from the chromatograms
of the standard aliquots.
W1 = Weight of the working standard taken in mg.
 W2 = Weight of the working Test taken in mg
`   P=Potency of standard
Avg .Weight=Average weight in mg
Trials Drug content (in %)**
(Mean ± S.D.)
Trials Drug content (in %)**
(Mean ± S.D.)
P5 101.53 ± 7.89 L1 98.26±2.56
P6 98.58 ± 0.99 L2 99.45±1.12
P7 97.22 ± 1.78 L3 103.54±0.12
P8 99.29 ± 1.07 L4 97.25±0.45
P9 99.24 ± 2.68
P10 96.24 ± 0.81
P11 97.90 ± 1.92
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P12 101.18 ± 1.84
P13 100.54 ± 1.35
**n=3                          
  Table No. 40:  Drug content uniformity 
9.3 Dissolution 
for pseudoephedrine HCl B.P
Apparatus: USP II (paddle) dissolution test apparatus 
Speed: 50rpm
Medium:  Demineralized water    
Volume: 900ml
Time:  2, 4, 6,8and 10   hrs
Temperature: 370 ± 0.50C
λ max:  257nm
 Standard:  65.0mg pseudoephedrine HCl B.P was taken in 50ml volumetric flask shacked
vigorously up to dissolved with help of sonicator and  Up to 50ml volume was
made up  with demineralized water.   
5ml  was  taken  from  above  solution  and   50ml  volume  was  made  up   with
demineralized water.   
Calculation:
Factor: -     1    x    W1   x     5  x   500 x  P1   x   100
       As          100       5     L.C      100
            W1 =   weight of working Standard
L.C= Label claim in mg
P1 =    % potency of working Standard 
As=   Absorbance of standard
For loratadine USP:
Apparatus: USP II (paddle) dissolution test apparatus 
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Speed: 50rpm
Medium: 0.1M Hydrochloric Acid
Volume: 500ml
Time: 30, 45 min.
Temperature: 370 ± 0.50 C
λ max:  280nm
Standard: 20.0mg loratadine was taken in 100ml volumetric and vigorously shacked up to
dissolved with help of sonicator. Then volume was made up to 100ml with 0.1M
hydrochloric acid. 5 ml was taken from above solution and volume was made up
to 100ml with 0.1M hydrochloric acid.
Procedure:    6 tablets was taken  and each one transfered to a vessel containing 500ml of 0.1M
HCl. Apparatus was switched on and care taken to ensure no air bubble of the
surface of the tablets. After 30 minuets 10ml of sample was pipette out from each
vessel at time 30 and 45 minuets and filtered. The filtrated taken and absorbance
was noted.
Calculation  
Factor: -     1    x    W1   x     5  x   500 x  P1   x   100
       As          100       5     L.C      100
W1 =   weight of working Standard
L.C= Label claim in mg
P1 =    % potency of working Standard
As=   Absorbance of standard
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Time
(min
)
Formulation
Innovator L1 L2 L3 L4
15 64.23 57.45 63.6 56.25 69.2
45 98.56 92.33 97.82 108.25 102.6
 Experimental work
Table No. 41: Dissolution profile of IR in different trials (0.1N HCl) 
           
9.3 Kinetics of release 
Model dependent approach
In order to analyze the release mechanism, several release models were tested such as:
Higuchi 
Q t=KH √t
Where Qt is the amount of drug released at time t and KH is the Higuchi release rate; this is the
most widely used model to describe drug release from pharmaceutical matrices.
Zero Order : 
Qt=Q0+K0 +t
Where Qt is the amount of drug released at time t, K0 is the apparent dissolution rate constant or
zero order release constant, and Q0 is the initial concentration of the drug in the solution resulting
from a burst effect; in this case the drug release runs at a constant rate.
First Order:
In Qt=InQ0+K1
Where  K1 is  the  first  order  release  constant;  in  this  case  the drug  released  at  each  time is
proportional to the residual drug inside the dosage form.
Korsmeyer–Peppas:
Qt/Q∞=Kktn
Where Kk is a constant incorporating structural and geometric characteristics of the drug dosage
form and n is the release exponent, indicative of the drug release mechanism.
Estimation of parameters using Korsemayer equation 
log Mt /Mα  = Log k + n log t
Where,
Mt /Mα = the fractional release of the drug 
t = release time 
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k = a constant depending on the structural and geometric characteristics of the release 
device.
n = the time exponent indicative of the release mechanism
In order to compare the differences for the release profiles between the tablets and their halves a
simple model independent approach using a difference factor (f1), a similarity factor ( f2). 
The cumulative amount of pseusdoephedrine HCl released from the formulations at  different
time  intervals  was  fitted  to  zero  order  kinetics  using  least  square  method  of  analysis.  The
correlation coefficient between the time and cumulative amount released was calculated to find
the fitness of the data to zero order kinetics. The data were also subjected to first order kinetics
by  determining  the  correlation  coefficient  between  the  time  and  the  log  percent  of
pseusdoephedrine  HCl to be released  from the formulation.  The data were also subjected to
Higuchi’s  model by plotting the cumulative percent  pseudoephedrine  released  against  square
root of time. Fitness to Higuchi’s model was assessed by determining the correlation coefficient
between the square root of time and the cumulative amount of pseusdoephedrine HC released
from the formulations. 
The cumulative percent of drug released from the formulations was plotted against time on log–
log scale, and analyzed for linearity using Least-Squares Method. Calculating correlation 
coefficients between time and the cumulative percent of drug released on log–log scale tested the
fitness of the data. 
Release exponent Release mechanism
0.5 Fickian diffusion 
0.5< n <1 Non-fickian diffusion/Anomalous transport
1 Case-II transport/Zero order release
> 1 Super case II transport
Table No.42: Release exponent and release mechanism 
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Time
(hrs)
                                                    Trials
Inno. P 5 P 6 P 7 P 8 P9 P 10 P 11 P12 P13
2 31.81 55.96 58.75 54.24 50.23 45.26 56.26 48.45 45.24 42.28
4 55.5 77.28 68.36 66.13 62.45 55.92 73.92 64.23 56.13 50.63
6 64.23 95.88 80.65 88.65 79.08 63.63 89.23 79.6 74.23 70.56
8 77.96 99.27 90.75 95.11 88.28 78.76 97.42 89.26 89.62 85.66
10 86.96 99.65 98.05 97.16 92.67 89.72 99.23 96.76 100.28 92.73
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Table No. 43: Zero order release profile 
Cumulative percent drug dissolved Vs time (D.M. water)
Page 78
 Experimental work
Figure  No.   11.1 Figure   No.  11.2
                         
Figure  No.  11.3
Table No.44: First order release profile
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Log Percent Drug undissolved  V/s Time
 
Figure no12.1
 
Figure no12.2
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Formulation
Time Inno. P5 P6 P7 P8 P9 P10 P11 P12 P13
0 2 2 2 2 2 2 2 2 2 2
2 1.83 1.64 1.61 1.66 1.69 1.73 1.64 1.71 1.73 1.76
4 1.64 1.35 1.50 1.52 1.57 1.64 1.41 1.55 1.64 1.69
6 1.55 0.61 1.28 1.05 1.32 1.56 1.03 1.30 1.41 1.46
8 1.34 -0.13 0.96 0.68 1.06 1.32 0.41 1.03 1.01 1.15
10 1.11 -0.45 0.29 0.45 0.86 1.01 -0.11 0.51 -0.10 0.86
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SRT*                                                              Trials
Inno. P 5 P 6 P 7 P 8 P9 P 10 P 11 P12 P12 P13
1.412
31.81 55.96 58.75 54.24 50.23 45.26 56.26 48.45 45.24 45.24 42.28
2 55.5 77.28 68.36 66.13 62.45 55.92 73.92 64.23 56.13 56.13 50.63
2.449 64.23 95.88 80.65 88.65 79.08 63.63 89.23 79.6 74.23 74.23 70.56
2.828 77.96 99.27 90.75 95.11 88.28 78.76 97.42 89.26 89.62 89.62 85.66
3.162 86.96 99.65 98.05 97.16 92.67 89.72 99.23 96.76 100.28 100.28 92.73
Table No. 45:Higuchi release profile 
 SRT*= Square root of time
Cumulative percent drug dissolved Square root of time:
Figure No. 13.1
Figure No. 13.2
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Figure No. 13.3
Log
time
Log fraction drug released
Inno. P5 P6 P7 P8 P9 P10 P11 P12 P13
0.301 -0.497 -0.252 -0.230 -0.265 -0.299 -0.344 -0.249 -0.314 -0.344 -0.373
0.602 -0.255 -0.111 -0.165 -0.179 -0.204 -0.252 -0.131 -0.192 -0.250 -0.295
0.778 -0.192 -0.018 -0.093 -0.052 -0.101 -0.196 -0.049 -0.099 -0.129 -0.151
0.903 -0.108 -0.003 -0.042 -0.021 -0.054 -0.103 -0.011 -0.049 -0.047 -0.067
1 -0.060 -0.001 -0.008 -0.012 -0.033 -0.047 -0.003 -0.014 0.001 -0.032
Table No.46:Korsemayer plot
Log fraction drug released and Log time
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Figure No. 14.1
Figure No. 14.2
Figure No.14.3
 
Page 83
 Experimental work
 Table No.47: In vitro dissolution kinetics of matrix tablets 
9.4 Comparison of dissolution profile:
9.4.1 Purpose of dissolution profile comparison:
• In order to compare the differences in the release profile between the references to test
simple model independent approach using a difference factor (f1) and similarity factor
has been adopted by FDA.
• For accepting product sameness under SUPAC-related changes.
• To waive bioequivalence requirements for lower strengths of a dosage form.
• To support waivers for other bioequivalence requirements.
 9.4.2 Model Independent Approach Using a Similarity Factor
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Formulation Zero
order
First
order
Higuchi n value
Inno 0.981 0.994 0.994 0.614
P5 0.950 0.977 0.950 0.379
P6 0.933 0.953 0.933 0.511
P7 0.993 0.958 0.972 0.394
P8 0.993 0.996 0.993 0.400
P9 0.962 0.980 0.962 0.418
P10 0.934 0.987 0.934 0.370
P11 0.990 0.992 0.934 0.438
P12 0.988 0.988 0.990 0.510
P13 0.997 0.999 0.988 0.519
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A simple model independent approach uses a difference factor (f1) and a similarity factor
(f2)  to  compare  dissolution  profiles.  The  difference  factor  (f1)  calculates  the  percent  (%)
difference between the two curves at each time point and is a measurement of the relative error
between the two curves:
             f1= {[ Σ t=1n | R t –T t | ] / [Σ t=1n R t ] }·100
                               
      where n is the number of time points, Rt is the dissolution value of the reference  batch at
time t, and Tt is the dissolution value of the test  batch at time t. The similarity factor (f2) is a
logarithmic  reciprocal  square  root  transformation  of  the  sum  of  squared  error  and  is  a
measurement of the similarity in the percent(%)dissolution between the two curves
  A specific procedure to determine difference and similarity factors is as follows:
1. Determine the dissolution profile of two products of the test and reference products.
2. Using the mean dissolution values from both curves at each time interval, calculate the
difference factor (f1) and similarity factor (f2) using the above equations.
3. For curves to be considered similar, f1 values should be close to 0, and f2 values should be
close to 100. Generally, f1  values up to 15 (0-15) and f2  values greater than 50 (50-100)
ensure sameness or equivalence of the two curves and, thus, of the performance of the
test and reference products.
This model independent method is most suitable for dissolution profile comparison when three to
four  or  more  dissolution  time  points  are  available.  As  further  suggestions  for  the  general
approach, the following recommendations should also be considered:
1. The dissolution measurements of the test and reference batches should be made under
exactly the same conditions. The dissolution time points for both the profiles should be
Page 85
 Experimental work
the same (e.g.,  15, 30, 45, 60 minutes).  The reference batch used should be the most
recently manufactured product.
2. Only one measurement should be considered after 85% dissolution of both the products. 
3. To allow use of mean data, the percent coefficient of variation at the earlier time points
(e.g., 15 minutes) should not be more than 20%, and at other time points should not be
more than 10%.
4. The mean dissolution values for Rt can be derived either from (1) last t (reference) batch
or (2) last two or more consecutively manufactured batches.
Formulation F2 value
P5 32.01
P6 38.42
P7 37.26
P8 45.56
P9 60.24
P10 34.43
P11 44.65
P12 48.03
P13 56.65
Table No. 48: Similarity factor 
Formulation F1 value
P5 34.93
P6 25.31
P7 26.80
P8 17.77
P9 5.318
P10 31.47
P11 19.54
P12 15.49
P13 8.02
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 Table No.49: Difference factor 
10. Stability studies of optimized formulation
The stability study was carried out by keeping them at 40oC/75% RH for 3 month to
assess their stability with respect to their physical appearance and release characteristics. The
physical characteristics like weight variation, hardness, friability, disintegration time, and in vitro
release profile were determined at interval of 15, 30, 45 and 60 days by packaging the tablets in
sealed aluminum foil  and kept in humidity chamber.
Formulation Stability
study
period
(Days)
Weight
variation
Hardness Friability Drug
content
Pn
Drug
content
L4
L4+P9
0
596-612 4-5 0.23 96±0.39
95.36
15 595-615 6-7 0.51 96.2 ±0.56
30 589-615 6-7 0.52 95.8±0.31
45 598-609 5-6 0.50 97.2±0.33
60 588-618 2-3 0.79 96.2 ±0.56
L4+P13
0
595-608 6-7 0.49 97±0.23
15 598-609 4-5 0.49 97.2±0.26
30 595-615 4-5 0.42 96.8±0.65
45 596-612 2-3 0.43 98.2±0.21
60 589-615 2-3 0.72 95. ±0.26
Table No. 50: Evaluation of tablets during stability study period   (40oC/75%RH) 
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Time
(Hrs) 0 day 15days 30 days 45  days 60 days
2 42.28 44.24 45.2 47.96 46.03
4 50.63 60.65 55.15 65.25 60.56
6 70.56 69.23 66.5 78.15 71.13
8 85.66 79.35 77.5 85.5 80.3
10 92.73 94.25 92.5 95.5 92.95
Table  No.51:Zero order  release  profile  of  P13 at  0,  15,  30,  45  and 60  days  during the
stability period 
Figure No. 15
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Time
(Hrs) 0 day 15days 30 days 45  days 60 days
2 45.26 46.24 45.2 44.96 46.23
4 55.92 58.65 55.15 56.25 59.56
6 63.63 69.23 66.5 65.15 65.13
8 78.76 79.35 77.5 77.5 78.3
10 89.72 90.25 92.5 91.5 92.95
Table No. 52:Zero order release profile of P9 at 0, 15, 30, 45 and 60 days during the stability  period
   Figure No. 16
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11. Results and discussion 
In the present investigation sustained release matrix as well as immediate release bilayer tablets
was prepared of two drug using hydrophilic polymer, HPMC K100M and different ingredient.
The  hydrophilic  matrix  tablets  were  prepared  by  different  method  wet  granulation  direct
compression and slugging technique. 
1.  Preformulation Study:
1. API Characterization Study:
1.1 Angle of repose:
Pseudoephedrine HCl was 35.940 and it was passable as result shown in table 14.
Loratadine was cohesive in nature.
1.2 Bulk density and tapped density:
Tapped  density  was  higher  then  bulk  density  and  result  are  shown  in  table  15 and
respectively.  Tapped density of pseudoephedrine HCl and loratadine was found 0.683
and 0.293 respectively.
1.3 Compressibilty index:
The  flow characteristics  of  pseudoephedrine  HCl  was  free  flow and  loratatdine  was
cohesive and drug stick with fennel result shown in  table no.15 and Hauusner’s ratio
result show in table 17.
1.3  pH dependent solubility Study: 
pH of pseudoephedrine HCl and loratadine in 10% solution in methanol  was found to
4.18 and 6.8 respectively.  The pH dependent solubility study was carried out by using
different pH buffer solution 0.1 N HCl ,D.M water , pH 4.5 acetate buffer, pH 5.5 acetate
buffer and pH 6.8 phosphate buffer. Study showed solubility of loratadine was more in
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pH  1.2  (0.1  N  HCl)  35.66mg/ml  and  for  pseusdoephedrine  HCl  556.86  mg/ml  as
indicated in table no.25 and 24 respectively.
1.3   Sieve Analysis of API:
The sieve analysis carried out by using mechanical shaker, showed that the    average
particle  size  of  pseudoephedrine  HCl  was  250µm  as  given  in  table  no.20  for
pseudoephedrine HCl. For loratadine micro analyzer is used and average particle size was
10 micrometers. 
1.4. Loss on Drying (LOD):
As calculated,  moisture content  of pseudoephedrine HCl 0.42% and loratadine 0.37%
respectively.
The flow properties of pure drugs were carried out and the results indicate that pseudoephedrine
HCl has good flow and loratadine poor flow property and cohesive nature. In order to overcome
this problem wet granulation technique was adopted using starch paste as binder to impart good
flow as well as compressibility for loratadine because granules has good flow as compare to pure
drug and for pseusdoephedrine HCl wet granulation ,direct compression and slugging used.
2. Compatibility Study:  
Drug–Excipients  compatibility  study  of  pseudoephedrine  HCl  and  loratadine  with  different
categories of excipients was carried out. The study was carried out at accelerated conditions of
temperature and humidity like 40°C/75%RH, and noted their physical appearance, and release
profile after 15,30,45and 60 Days and compared with initial value and result shown in  table
26and 27.
3. Evaluation of Formulation Parameters:
Evaluation was divided in mainly in to
- Pre compression parameters and
- Post compression parameters.
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 Pre compression parameters include loss on drying of dried granules and final blend,
bulk density, tapped density, Carr’s index, Houser’s ratio and sieve analysis. In post compression
parameters  average  weight,  thickness,  hardness,  disintegration  time  and  friability  were
determined.
3.1. Pre Compression Parameters:
• % LOD of  dried  granules  maintained in  that  level  2  to3%  by drying  at  105°C and
optimize drying time (5min.) shown in tables no. 37 and 38.
 Bulk density in the range 0.508 – 0.593 gm/ml for Pn and 0.505 to 0.575 for Ln
trails
 Tapped density in the range 0.54-0.695 gm/ml for Pn and 0.641 to 0.594 for Ln
trials 
 Carr’s Index ranging 
                        P1 to P4 6.47 to9.92
      P5 20.23
      P6 to P13 11.56 to 15.29 to 23.56 
      Ln trails 15.05 to 20.08
 Hauser’s ratio in the range 1.1-1.2 shows the good flow characteristics for both.
• Wet granulation method was adapted in trials P1 to P4 trials and poor flow
and color of granules was change during drying. 
• Direct  compression  method  was  adapted  in  trial  P5  and  sticking  was
observe,  powder blend shows poor flow which causes  weight  variation
and problem in content uniformity.
• In P6 to P13 trials, granules was passable and pre compression.
• In L1 to L4, it was found that granules have good flow property.L1 trials
D.T  was  higher  so  we  reduce  binder  concentration  and  molting  also
present so we change ratio in extra granular and intra granular.  
3.2 Post compression parameter:
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 The tablets were evaluated for physical  characteristics like weight variation,      hardness,
friability and drug content.
 The weight variation test was carried out for bilayer tablets and the values are shown in
table no. 39 respectively. The weight variation values of first four trials the tablets are in
the range of 568 mg to 630 mg for bilayer tablets, which is more than 5% indicating that
the variation in the weight of the tablets is out official limits but  for remaining trails
within range.
 The hardness test was carried out using Monsanto hardness tester. The hardness of the
bilayer tablets are shown in table no. 39 respectively. The tablet hardness was found to
be  uniform and  in  the  range  of  approximate  4  to  5  kg/cm2  which  indicates  that  the
prepared bilayer tablets are mechanically stable.
 The  friability  test  was  carried  out  by  Roche  friabilator.  The  percentage  friability  of
bilayer tablets are shown in table no. 39. They are in the range of 0.21% to 0.73 % for
bilayer tablets. They are less than the standard limit of 1% indicating that the prepared
tablets are mechanically stable. 
Drug content uniformity
The percent drug content values of bilayer tablets of each formulation are shown in table no. 40
for both layer. They are in the range of 95% to 102% which is within standard limit of ± 5%. It
indicates uniform distribution of drug in the tablets of each formulation. 
In Vitro drug release studies:
• Drug release form P6 trial was at higher rate and trials P7, P8 intermediate  
• P10 to P 12 release rate retard as concentration of DCP increase.
• P9 and P13 trials only contain only DCP as diluents so release was slowest as compared
to other. (Table No. 42)
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• The correlation coefficient values of zero order and first order release profiles of  matrix
tablets are 0.981 ,0.950 ,0.933, 0.972, 0.993 ,0.962 ,0.934 ,0.990, 0.988 ,0.99 and 0.994 ,
0.97 ,0.953, 0.95, 0.996, 0.980, 0.987, 0.992 ,0.999 ,0.988 respectively.(Table No. 47)
• The correlation coefficient values of Higuchi plot are 0.994, 0.950, 0.933, 0.97, 0.993,
0.962, 0.934, 0.93, 0.990 and 0.988 for matrix tablets. (Table No. 45)
• P5, P6, P6, P8, P10, P11, P13 trials followed first order of kinetics.
• P7  trials follows zero order kinetics 
• Only P13 trials follow Higuchi model
• Dissolution profile of loratadine was given in table no.39.
f1 and f2 Value:
Similarity  factor  (F2)  was  calculated  between  innovator  formulation  and  our  formulation.
Similarity factor  value in the range of 50-100 indicates that  there is similarity in the release
profile of the formulations.
• In case of tablet formulation P5 to P13 shown f1  value34.93 ,25.31, 26.80, 17.77, 5.318,
31.47 ,19.54 ,15.49 ,8.02 respectively,  and  f2  value 32.01 ,37.26, 45.56, 60.24, 34.43,
44.65, 56.65 and 48.03 respectively.(Table no.48 and 49)
• The diffusional exponent values (n) for and  P6,P7,P8 and P9 ranged from 0.32 to 0.41
indicating that the drug release from the  matrix tablets followed fickian diffusion.
• The diffusional exponent values (n) for P10, P11, P12 and P13 ranged from 0.41 to 0.61
indicating that the drug release from the matrix tablets followed anomalous diffusion(non
fickian).
Stability studies
 The stability studies of the optimized matrix as well as bilayer formulation were done for about
2 months by sealing the tablets in aluminum foil and kept in humidity chamber.
• The physical characteristic like weight variation, hardness, friability, percent drug content
during and in vitro release profile were determined at interval of 15, 30,45 and 60 days. 
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• The value of weight variation, hardness, friability and percent drug content during stability
study for bilayer tablets are shown in the table 50. These values indicate that there was no
significant change when compared with fresh samples.
• Dissolution study was carried out at each time interval for all the optimized formulation
during the stability studies.
• The cumulative percentage drug released Vs time profile for matrix tablets are shown in
table 51 and 52, and figure 15 and 16 respectively. The results indicate that there is no
significant change in the release profile of the formulations during the stability studies. 
• The data obtained from the stability studies of the optimized formulation indicates that the
tablets are stable
Selection of optimized formulation
f1 and f2 Value
In case of matrix tablets for the selection of optimized formulation the similarity factor and the
difference factor are calculated between the marketed formulation and our prepared formulation.
Similarity factor value in the range of 50-100 and difference factor value in the range of 0-15
indicates that there is similarity in the release profile of the two formulations.
• Formulation P9 showed the highest f2 value of 60.24 and lowest f1 value 5.318 and P13
showed the highest f2 value of 56.65 and lowest f1 value 8.02.
• The diffusional  exponent values (n) for P13 was 0.61 indicating that the drug release
from the matrix tablets followed anomalous diffusion(non fickian).
In Vitro drug release studies:
• The correlation coefficient values of Higuchi plot of P13 0.988 for matrix tablets. The
correlation coefficient values are close to one which indicates that the drug release is by
diffusion mechanism
• P13 trials only contain only DCP as diluents so release was slowest as compare to other
because its insoluble in water.
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Drug-excipients interaction studies 
• The optimized formulations were subjected to FTIR studies to confirm whether or not
there is drug polymer interaction. 
• The results of the FTIR studies indicate that there was no interaction between the drug
and polymers used in the formulation.
Page 94
Conclusions
12. Conclusions 
In the present study sustained release matrix as well as immediate release bilayer tablets
was prepared using two hydrophilic polymers HPMC K100M and ethyl cellulose. From
the results following conclusions can be drawn.
 The release of pseusdoephedrine HCl and loratadine from the bilayered tablets
was analyzed by plotting the cumulative percent drug release v/s time. The initial
high amount of loratadine release can be attributed to the release of drug from the
immediate release layer  of  the formulations and the sustained release  layer  of
pseudoephedrine HCl formulations exhibited prolonged drug release.
 Dissolution  of  loratadine  was  little  affected  by  addition  of  SLS  because  the
average particle size of drug was 10 µm 
 The correlation coefficients of all the formulations for first order release kinetics
were found higher when compared to those of zero order kinetic indicating that
the drug released from all the formulations followed first order kinetics.
 Analysis of the dissolution profile on the basis of Higuchi’s model suggested that
the drug release was basically swelling and diffusion controlled.
 Data from the Korsemayer model suggested that drug release from formulations
P12 andP13 was non-Fickian (anomalous) diffusion.
 While maintaining the HPMC K100M and drug level constant in the controlled
release tablet formulations investigated, it was found that the type and level of
excipients influenced the rate and extent of pseusdoephedrine HCl release.
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 The percent average difference, based on f2 values, between dissolution profiles of
formulations containing soluble excipients compared to formulations containing
insoluble excipients was in the range of 15–20%, indicating dissimilarities in the
release profiles. 
 The  percent  average  difference  between  dissolution  profiles  of  formulations
containing a similar type of excipients (i.e., soluble or insoluble excipients) was in
the range of 5–10%, indicating similarities in the profiles. 
 The insoluble excipients,  especially DCP, caused  the drug to  be released  at  a
slower  rate  and  to  a  lesser  extent  than  the  soluble  excipients  investigated.
Formulations containing insoluble diluents  (P9 and P13) were  more similar  to
innovator product.
 Intermediate release profiles were obtained for pseudoephedrine HCl containing
lactose  and  DCP  were  used  in  the  formulation.  The  release  mechanism  of
pseusdoephedrine HCl from each tablet formulation was described by Peppas’s
equation [non-Fickian (anomalous) diffusion]. 
  Different type diluents type and level used in the formulation did not have an
impact on the release mechanism of pseusdoephedrine HCl from the tablets. The
results  of  this  study  provide  useful  information  on  formulation  optimization
during development of controlled release tablet formulations.
 FT-IR studies revealed that there was no chemical interaction between the drug
and the various polymers used in the study.
 Stability studies indicated that there was no significant change in the properties of
matrix as well as bilayered tablets.
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